

**CURRICULUM VITAE**  
**Lorraine Portelance, MD, FASTRO, FRCPC, DABR**

---

1. Date : July 6 th, 2017

**I. PERSONAL**

2. Name Lorraine Portelance  
3. Office Phone 305-243-4341  
4. Office Address: 1475 NW 12 Avenue, Suite 1500, Miami, Fl. 33136  
5. Current Academic Rank: Associate Professor Clinical Educator Track  
6. Primary Department: Radiation Oncology  
7. Secondary or Joint Appointment: None  
8. Citizenship Canadian  
9. Visa Type Permanent resident USA

**II. HIGHER EDUCATION**

**11. Institutional:**

|                         |  |           |
|-------------------------|--|-----------|
| Teaching Scholar        | McGill University; Montreal, QC, Canada      | 2003-2004 |
| MD                      | University of Montreal; Montreal, QC, Canada | 1987-1992 |
| BSc in Physical Therapy | McGill University; Montreal, QC, Canada      | 1981-1984 |

**12. Non-Institutional:**

Post-Doctoral Fellowship in Radiation Oncology/Gynecological Cancer Management  
Mallinckrodt Institute, St-Louis, MI 1998-1999

Radiation Oncology Residency; University of Montreal, Montreal, QC, Canada 1992-1997

**13. Certification and Licensure:**

**Certification**

|  |      |
|--|------|
| Diplomate, American Board of Radiology                               | 2000 |
| Fellow, Royal College of Physicians and Surgeons of Canada           | 1998 |
| Specialist Certificate in Radiation Oncology, Quebec Medical College | 1997 |

**Licensure**

|  |           |
|--|-----------|
| Medical License, Florida Department of Health Board of Medicine, FL        | 2012-pres |
| Faculty Certificate, Florida Department of Health Board of Medicine, FL    | 2010-2012 |
| Medical License, Quebec College of Physicians; QC, Canada                  | 1998-2010 |
| Medical License, Missouri State Board for Registration of Healing Arts; MI | 1998      |
| Medical License, Medical Council of Canada                                 | 1994      |

**III. EXPERIENCE:****14. Academic:**

|   |           |
|---|-----------|
| Associate Professor, Department of Radiation Oncology<br>Miller School of Medicine; University of Miami, FL         | 2011-pres |
| Assistant Professor Department of Oncology<br>McGill University; Montreal, QC, Canada                               | 2002-2010 |
| Chair, Oncology Department Interdisciplinary Oncology Training Committee<br>McGill University; Montreal, QC, Canada | 2002-2010 |
| Radiation Oncology Residency Program Director<br>McGill University; Montreal, QC, Canada                            | 2003-2006 |
| Adjunct Professor, Department of Oncology<br>McGill University; Montreal, QC, Canada                                | 1999-2002 |

**15. Hospital Appointments:**

|  |           |
|--|-----------|
| Radiation Oncologist, Lennar Foundation Medical Center, Miami, FL              | 2016-pres |
| Radiation Oncologist, Bascom Palmer Eye Institute, Miami, FL                   | 2010-pres |
| Radiation Oncologist, Sylvester Comprehensive Center, Miami, FL                | 2010-pres |
| Radiation Oncologist, Jackson Memorial Hospital, Miami, FL                     | 2010-pres |
| Radiation Oncologist, University of Miami Hospital, Miami, FL                  | 2010-pres |
| Radiation Oncologist, Lakeshore General Hospital, Dorval, QC, Canada           | 2008-2010 |
| Radiation Oncologist McGill University Health Centre, Montreal, QC, Canada     | 2002-2010 |
| Radiation Oncologist, CH des Valleees de L'Outaouais, Gatineau, QC, Canada     | 1999-2000 |
| Fellow, Radiation Oncology, Mallinckrodt Institute of Radiology, St. Louis, MI | 1998-1999 |
| Physical Therapist, Notre-Dame Hospital, Montreal, QC, Canada                  | 1984-1987 |

**16. Non-Academic: N/A****17. Military: N/A****IV. PUBLICATIONS:****18. Books and Monographs Published:**

1. Erickson BA, Olawaiye AB, Chen L-m, Bermudez A, Grendys EC, Grigsby PW, Hagemann IS, Oliva E, **Portelance L**, Wolfson AH, Mutch DG. Cervix Uteri. Amin MB, Edge SB, Greene FL, Schilsky RL, Gaspar LE, Washington MK, Sullivan DC, Brierley JD, Balch CM, Compton CC, Hess KR, Gershewald JE, Jessup JM, Madera M, Asare EA, Gress DM, Meyer LR, Wichester DP, Brookland RK, Byrd DR. Cervix Chapter, 649-659, AJCC Cancer Staging Manual, 8th edition. Springer International Publishing. Switzerland. (2017)
2. **Portelance L**, Rezvani M. Intra and Extrahepatic Book chapter. In: Gaffney D. Radiation Oncology Imaging and Treatment, 258-268, Amyris publishing. (2012)
3. **Portelance L**. Hypofractionation for Gastrointestinal Cancer (section editor). In: Pollack A, Ahmed M, (Eds). Hypofractionation, scientific concepts and clinical experiences, 133-173, Ellicott City: Lumitext publishing. (2011)
4. **Portelance L**, Dawson L Hypofractionated Radiation Therapy in the Management of Primary Liver Cancer. In:Pollack A, Ahmed M, (Eds). Hypofractionation, scientific concepts and clinical experiences, 147-163, Ellicott City: Lumitext publishing. (2011)
5. Crane CH, Meyer J. **Portelance L**. Stereotactic Radiotherapy for Pancreatic Cancer. In: Pollack A, Ahmed M, (Eds). Hypofractionation, scientific concepts and clinical experiences, 163-172, Ellicott City: Lumitext publishing. (2011)
6. Germain I, Jolicoeur M, Kavanagh M, **Portelance L**, Roy I, Vincent F, Vincent L.S., Guide sur l'utilisation d'un fractionnement accéléré de radiothérapie pour le traitement du cancer du sein, Comité de l'évolution des pratiques en oncologie (CEPO), Division de la lutte contre le cancer, Monograph, Bibliothèque nationale du Québec (2006)

#### 19. Juried or Referred Journals Article or Exhibitions:

1. Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, EITawil R, Kwon D, Venkat S, **Portelance L**, Yechieli R. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovascular and Interventional Radiology. 39(11):1-9. (2016)
2. Gaffney DK, King B, Viswanathan AN, Barkati M, Beriwal S, Eifel P, Erickson B, Fyles A, Goulart J, Harkenrider M, Jhingran A, Klopp A, Koh WJ, Lim K, Petersen I, **Portelance L**, Small W Jr, Stewart A, Wiebe E, Wolfson A, Yashar C, Bosch W. Consensus Recommendations for Radiation Therapy Contouring and Treatment of Vulvar Carcinoma Int J Rad Onc Biol Phys. 95(4):1191-200. (2016)
3. Wolfson A, Reis M, **Portelance L**, Diaz DA, Zhao W, Gibb RK. Prognostic Impact of Clinical Tumor Size for Sub classifying Stage I and II Vaginal Cancer: A SEER Analysis. Gynecol Oncol. 141(2): 255-9. (2016)
4. Jones E, Beriwal S, Beyer D, Chino J, Jhingran A, Lee L, Michalski J, Mundt AJ, Patton C, Petersen I, **Portelance L**, Schwarz J, McCloskey S. An Analysis of Appropriate Delivery of Post-Operative Radiation Therapy for Endometrial Cancer Using the RAND/UCLA Appropriateness Method, Advances in Radiation Oncology. 1(1):26-34. (2015)

5. Khushman M, Dempsey N, Cudris Maldonado J, Loaiza-Bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CD, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, **Portelance L**, Sleeman D, Levi JU, Rocha Lima CM, Hosein PJ. Full Dose Neoadjuvant FOLFIRINOX is Associated with Prolonged Survival in Patients with Locally Advanced Pancreatic Adenocarcinoma. *Pancreatology*. 15(6): 667-73. (2015)
6. Lim K, Erickson B, Jurgenliemk-Schultz IM, Gaffney DK, Creutzberg CL, Viswanathan A, **Portelance L**, Beriwal S, Wolfson A, Bosch W, De Los Santos J, Yassar C, Jhingran A, Varia M, El Naga I, King B, Fyles T.; Variability in Clinical Target Volume Delineation for Intensity Modulated Radiotherapy in 3 Challenging Cervix Cancer Scenarios; *Pract Radiat Oncol*. 5(6):557-65. (2015)
7. Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, **Portelance L**, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W Jr, Gaffney DK. NRG Oncology/RTOG 0921: A Phase 2 Study of Postoperative Intensity-Modulated Radiotherapy With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer, *Int J Rad Onc Biol Phys*. 121(13):2156-63. (2015)
8. Viswanathan AN, Erickson B, Gaffney DK, Beriwal S, Bhatia SK, Lee Burnett O 3rd, D'Souza DP, Patil N, Haddock MG, Jhingran A, Jones EL, Kunos CA, Lee LJ, Lin LL, Mayr NA, Petersen I, Petric P, **Portelance L**, Small W Jr, Strauss JB, Townamchai K, Wolfson AH, Yashar CM, Bosch W. Comparison and Consensus Guidelines for Delineation of Clinical Target Volume for CT-and MR-Based Brachytherapy in Locally Advanced Cervical Cancer. *Int J Radiat Oncol Biol Phys*. 90(2):320-8. (2014)
9. Gaffney D, Jhingran A, Portelance L, Viswanathan A, Scheffer T, Weidhaas J, Small W. Radiation Therapy Oncology Group Gynecology Oncology Working Group: Comprehensive Results, *Int J Gynecol Cancer*. 24(5):956-62.(2014)
10. Klopp AH, Moughan J, **Portelance L**, Miller B.E., Salehpour M.R., Hildebrandt E, Nuanjing J, D'Souza D, Souhami L, Small W, Gaur R, Jhingran A. Hematologic Toxicity on RTOG 0418: a Phase II Study of Post-Operative IMRT for Gynecologic Cancer. *Int J Rad Onc Biol Phys*. 86(1) 83-90. (2013)
11. Hosein PJ, Macintyre J, Kawamura C, Cudris Maldonado J, Ernani V, Loaiza-Bonilla Arturo, Narayanan G, Ribeiro A, **Portelance L**, Merchan J, Levi JU, Rocha-Lima C. A Retrospective Study of Neoadjuvant FOLFIRINOX in Unresectable or Borderline Resectable Locally Advanced Pancreatic Adenocarcinoma. *BMC*. 12(199): 1-7 (2012)
12. Gay HA, Barthold JH, O'Meara E, Bosch WR, El Naqa I, Al-Lozi R, Rosenthal SA, Lawton C, Lee WR, Sandler H, Zietman A, Myerson R, Dawson LA, Willett C, Kachnic LA, Jhingran A, **Portelance L**, Ryu J, Small W, Gaffney D, Michalski JM . Pelvic Normal Tissue Contouring Guidelines for Conformal Radiation Therapy: a Radiation Therapy Oncology Group Consensus Panel Atlas. *Int J Rad Onc Biol Phys*. 83(3):353-362 (2012)
13. Jhingran A, Winter K, **Portelance L**, Miller BE, Salehpour MR, Gaur R, Souhami L, Small W, Berk L, Gaffney DK. A Phase II Study of Intensity-Modulated Radiation Therapy to the Pelvis for Post-Operative Patients with Endometrial Carcinoma: Radiation Therapy Oncology Group Trial 0418. *Int J Rad Onc Biol Phys*. 84(1):23-28 (2012)

14. Bloemers MC\*, **Portelance L**, Ruo R, Parker W, Souhami L. A Dosimetric Evaluation of Dose Escalation for the Radical Treatment of Locally Advanced Vulvar Cancer by Intensity-Modulated Radiation Therapy. *Medical Dosimetry*. 37(3):310-3. (2012)
15. Alfieri J\*, **Portelance L**, Souhami L, Steinert Y, McLeod P, Gallant F, Artho G. Development and Impact Evaluation of an e-Learning Radiation Oncology Module. *Int J Rad Onc Biol Phys*. 82(3):573-80. (2012)
16. Pavamani S, D'Souza D, **Portelance L**, Craighead P, Pearce A, Traptow L, Doll C. Image-Guided Brachytherapy for Cervical Cancer: A Canadian Brachytherapy Group Survey. *Brachytherapy*. 10(5):345-51. (2011)
19. Lim K, Small W, **Portelance L**, Gaffney D, Erickson B, De Los Santos J, Jhingran A, Fyles A. Consensus Guidelines for Intensity Modulated Radiation Treatment Volumes in the Treatment of Patients with Intact Cervix. *Int J Rad Onc Biol Phys*. 79(2):348-55. (2011)
20. Bloemers M\*, **Portelance L**. Preservation of Ovarian Function by Ovarian Transposition Prior to Concurrent Chemotherapy and Pelvic Radiation for Cervical Cancer. A Case Report and Review of the Literature. *Euro J of Gynaecol Oncol*. 31(2): 194-7 (2010)
21. Al-Halabi, H, **Portelance L**, Duclos M, Reniers B, Bahoric B, Souhami L. Cone Beam CT Based Three-Dimensional; Planning in High Dose Rate Brachytherapy for Cervical Cancer. *Int J Rad Onc Biol Phys*. 77(4):1092-7. (2010)
22. Bahig H, **Portelance L**, Legler C, Gilbert L, Souhami L. . Small cell carcinoma of the endometrium: Report of a case and review of the literature. *Minerva Gynecol*. 61(4):365-9. (2009)
23. Gaffney D, DuBois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, **Portelance L**, Sadoyze A, Potter R, Colombo A, Randall M, Mirza M, Trimble E. Patterns of Care for Radiotherapy in Vulvar Cancer: a Gynecologic Cancer Intergroup (GCIG) Study. *Int J Gynecol Cancer*. 19(1): 163-7. (2009)
24. Patone H, Souhami L, Parker W, Evans M, Duclos M, **Portelance L**. A Dosimetric Comparison of Two High-Dose-Rate Brachytherapy Planning Systems in Cervix Cancer: Standardized Template Planning versus Computerized Treatment Planning. *Brachytherapy*. 7(3):254-9. (2008)
25. Small W, Mell L K, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, **Portelance L**, Schefter T, Iyer R, Varia M, Winter K, Mundt AJ. Consensus guidelines for the Delineation of the Clinical Target Volume for Intensity Modulated Pelvic Radiotherapy in the Postoperative Treatment of Endometrial and Cervical Cancer. *Int J Rad Onc Biol Phys*. 71(2):428-34. (2008)
26. Hirsh V, Soulieres D, Duclos M, Faria S, DeVecchio P, Ofiara L, Ayoub JP, Charpentier D, Gruber J, **Portelance L**, Souhami L. Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Followed by Radiotherapy Concomitantly with Low Dose Paclitaxel and Gemcitabine in IIIA and IIIB Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2(10):927-32. (2007)

27. Patel S, **Portelance L**, Gilbert L, Tan L, Stanimir G, Duclos M, Souhami L. Analysis of Prognostic Factors and Patterns of Recurrence in Patients with Pathologic Stage III Endometrial Cancer. *Int J Rad Onc Biol Phys.* 68 (5):1438-45. (2007)
28. Vuong T, Kopek N, Ducruet T, **Portelance L**, Faria S, Bahoric B, Devic S. Conformal Therapy Improves the Therapeutic Index of Patients with Anal Canal Cancer Treated with Combined Chemotherapy and External Beam Radiation Therapy. *Int J Rad Onc Biol Phys.* 67(5):1394-400. (2007)
29. Gaffney D, DuBois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, **Portelance L**, Sadoyze A, Potter R, Colombo A, Randall M, Mirza MR, Trimble E. Practice Patterns of Radiotherapy in Cervix Cancer Among Member Groups of the Gynecologic Cancer Intergroup (GCIG), *Int J Rad Onc Biol Phys.* 68(2):485-90. (2007)
30. Faria S, Souhami L, **Portelance L**, Duclos M, Vuong T, Small D, Freeman CR. Absence of Toxicity with Hypofractionated 3-Dimensional Radiation Therapy for Inoperable Early Stage Non-Small Cell Lung Cancer. *Radiation Oncol.* 1(42):1-6. (2006)
31. Shenouda G, Mehio A, Souhami L, Duclos M, **Portelance L**, Belenkov A, Chow T. Erythropoietin Receptor Expression in Biopsy Specimens from Patients with Uterine Cervix Squamous Cell Carcinoma. *Int J Gynecol Cancer.* 16(2):752-6. (2006)
32. Souhami L, Corns R, Duclos M, **Portelance L**, Bahoric B, Stanimir G. Long Term Results of High Dose Rate Brachytherapy in Cervix Cancer Using Small Number of Fractions. *Gynecologic Oncology.* 97(2): 508-13. (2005)
33. Niazi TM, Souhami L, **Portelance L**, Bahoric B, Gilbert L, Stanimir G. High Dose Rate Brachytherapy (HDRB) in the Primary Treatment of Medically Inoperable Stage I-II Endometrial Carcinoma. *Int J Rad Onc Biol Phys.* 63(4):1108-13. (2005)
34. Vuong T, Franco E, Lehnert S, Lambert C, **Portelance L**, Nasr E, Faria S, Hay J, Larson S, Shenouda G, Souhami L, Wong F, Freeman C. Silver Leaf Nylon Dressing to Prevent Radiation Dermatitis in Patients Undergoing Chemotherapy and External Beam Radiotherapy to the Perineum. *Int J Rad Onc Biol Phys.* 59(3):809-14. (2004)
35. Grigsby PW, **Portelance L**, Williamson JF. High dose rate (HDR) Cervical Ring Applicator to Control Bleeding from Cervical Carcinoma, *Int J Gynecol Cancer.* 12(1):18-21. (2002)
36. **Portelance L**, Chao KS, Grigsby PW, Bennet H, Low D. Intensity Modulated Radiation Therapy Reduces Small Bowel, Rectum and Bladder Doses in Patients with Cervical Cancer Receiving Pelvic and Para Aortic Irradiation. *Int J Rad Oncol Biol Phys.* 51(1):261-6. (2001)
37. Grogan M, Thomas GM, Melamed I, Wong FLW, Pearcey RG, Joseph PK, **Portelance L**, Crook J, Jones K.D. The Importance of Hemoglobin Levels during Radiotherapy for Carcinoma of the Cervix. *Cancer.* 86(8):1528-36. (1999)

#### **Non Juried Published Work**

1. Small W., Mundt AJ., Anderson P., Creutzberg C., De Los Santo J., Gaffney D., Jhingran A., Portelance L., Schefter T., Riyer R., Varia M., Consensus Guidelines for the Delineation of the Intensity Modulated Pelvic Radiotherapy CTV in the Postoperative Treatment of Endometrial and Cervical Cancer. e-publication <http://rtog.org/gynatlas/main.html>. (2006)

## 20: Other Works, publications, and Abstracts:

1. Gajjar\* S, Yechieli R, Narayanan G, **Portelance L**. Outcomes Associated With a Combination of Radiation Therapy and Irreversible Electroporation for Pancreatic Cancer. *Int J Rad Onc Biol Phys*. 96(2):206. (2016) Poster presentation, ASTRO 2016
2. Viswanathan AN, Winter K, Miller BE, Xiao Y, Jhingran A, **Portelance L**, Bosch W, Matulonis U, Horowitz N, Mannel R.S, Souhami L, Erickson B, Small W, Gaffney D. Updated 4-year results for NRG oncology/ RTOG 0921: A phase II study of postoperative intensity modulated radiation therapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. *Int J Rad Onc Biol Phys*. 96 (2): 49-50. (2016) Oral presentation, gynecological scientific session, ASTRO 2016
3. Yassar C, Jhingran A, **Portelance L**, Visvanathan A. Computed Tomography Consensus CTV Contouring for IMRT in Intact Cervical Carcinoma. *Int J Rad Onc Biol Phys*, 96(2):13-14. (2016) Oral presentation, gynecological scientific session, ASTRO 2016
4. Dogan N, Lamichane N, Amestoy W, **Portelance L**. Dosimetric Evaluation of Magnetic Resonance-Image Guided Radiation Therapy 3-Source Co-60 and Linear Accelerator-Based Intensity Modulated Radiation Therapy Plans for Pancreas Stereotactic Body Radiation Therapy. *Int J Rad Onc Biol Phys*. 96(2):200. (2016) Poster presentation ASTRO 2016
5. Barkati M, King B, I. Fortin, **Portelance L**, Viswanathan AN, Fyles TW, Beriwal S, Alfieri J, Lim KS, Harkenrider MM, Small W, Klopp AH, Stewart A, Yashar CM, Bosch WR, Jhingran A, Jolicoeur M, Gaffney DK. Intensity Modulated Radiation Therapy for Vulvar Carcinoma: Changes in Practice Over 5 Years. *Int J Rad Oncol Biol Phys* 96(2):295–296 (2016) Poster presentation ASTRO 2016
6. Tinoco G, Palacio S, Sandoval A, Kwon D, Pollack T, Akunyili I, Rocha Lima CM, **Portelance L**. Influence of Age on Outcomes in Pancreas Adenocarcinoma (PAC): A single Institution Experience. *J Clin Oncol*. 34:e15744 (2016)
7. Kodyan J, Reis I, **Portelance L**, Pearson M, Slomovitz B, De La Garza J, Nieves-Neira W, Adams B, Wolfson AH. Impact of adjuvant therapy on patient survival in stage I/II high-intermediate risk endometrial cancers *Int J Rad Onc Biol Phys* (2015) Poster presentation ASTRO 2016
8. Palacio S, Hosein PJ, Levi JU, Merchan JR, Monge J, Portelance L, Reis IM, Rocha Lima CM. Prevalence of radiologic evidence of metastatic pancreatic cancer at first post-operative restaging studies in patient undergoing pancreas cancer surgery with the intent to cure. *J Clin Oncol* 34:(S4):225. (2016) Poster presentation ASCO GI 2016
9. Garcia-Soto AE, Dauphin McKenzie N, **Portelance L**, Castillo RP, Pearson JM, Hu JJ, Lucci

- JA, Lin LL, Simpkins F. Phase I trial of nelfinavir added to cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. *J Clin Oncol.* 33(3):5619. (2015) Poster presentation, ASCO 2015
10. Carcas L, Macintyre J, Merchan JR, Hosein PJ, Akunyili I, Restrepo M, Garcia MT, **Portelance L**, Sleeman D, Levi JU, Rocha Lima CM. The value of tissue protein expression as a predictor of efficacy for first- or second-line therapy in metastatic pancreas ductal adenocarcinoma (PDAC) in patients receiving either gemcitabine based treatment or 5FU - based treatment. *J Clin Oncol.* 33(3):460 (2015) Poster presentation, ASCO 2015
  11. Neboori H, De La Zerda A, **Portelance L**, Castillo R, Wolfson A. Is quantifying the D2cc to bowel necessary during definitive HDR brachytherapy for patients with invasive cervical carcinoma? (Abstract) *Int J Radiat Oncol Biol Phys.*90(15):473. (2014) Poster presentation ASTRO 2014
  12. Khushman M, Hosein PJ, Velez M, Carcas L, Dammrich DJ, Hurtado-Cordovi J, Parajuli R, Pollack T, Macintyre J, Harwood AP, Bonilla AL, Akunyili I, Restrepo M, Merchan J, Narayanan G, **Portelance L**, Sleeman D, Levi J, Rocha Lima CM Updated survival analysis of patients with unresectable or borderline resectable locally advanced pancreatic adenocarcinoma (LAPC) treated with neoadjuvant FOLFIRINOX. *J Clin Oncol.* 32:e15197. (2014)
  13. Khushman M, Scherfenberg N, Hosein PJ, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, Macintyre J, Harwood AP, Bonilla AL, , Merchan J, Restrepo MH, Akunyili I, Narayanan G, **Portelance L**, Sleeman D, Levi J, Rocha Lima CM Safety and Efficacy of Neoadjuvant Folfirinox in patients with locally advanced pancreatic adenocarcinoma. *Annals of Oncology* 25(S4): iv210-253 (2014) Poster presentation ESMO 2014
  14. **Portelance L**, Kopek N, Hosein P, Restrepo M, Rocha-Lima C, Levi J, Mahmoud O, Ishkanian A, Narayanan G, A Multidisciplinary Approach to the Management of Patients Diagnosed with Stage IV Anal Canal Cancer; A Multi Institutional Retrospective Study; American Radium Society Annual Proceedings. 76:98 (2014) Best poster awards, ARS 2014
  15. **Portelance L**, Zhang, Kopek N. A Dosimetric Comparison of Endorectal Brachytherapy, Tomotherapy, Linac based Stereotactic Body Radiotherapy (SBRT) and Cyberknife for the Delivery of a Rectal Tumor Boost. American Radium Society Annual Proceedings 76:99 (2014) Poster presentation ARS 2014
  16. Castellanos R, Ernaji V, Darda Bayraktar U, **Portelance L**, Montero AJ, Rocha Lima CM, Hosein PJ. A retrospective study of neoadjuvant DCF (docetaxel, cisplatin, 5-fluorouracil) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (GC). *J Clin Oncol.* 31(4S): 138. (2013) Poster presentation ASCO GI 2013
  17. Register SP, **Portelance L**, Deukwoo K, Twiggs L, Pearson JM, Lucci J, Wolfson A. The role of adjuvant therapy in stage III endometrial cancer. Proceedings of the American Radium Society (ARS) Annual Meeting (2012) Oral presentation ARS 2012
  18. Cohen D\*, **Portelance L**, McDuffie K and Wolfson A. A cost analysis of two different

- planning strategies for the delivery of vaginal vault brachytherapy. *Int J Rad Onc Biol Phys.* 84(3S):97. (2012) Oral presentation ASTRO 2012
19. Mahmoud OM, Zia S, Kwon D, Abramowitz M, Lally B and **Portelance L**. A comparative study of conventional radiation therapy versus intensity modulated radiation therapy in the management of patients with anal canal cancer. *Int J Rad Onc Biol Phys.* 84 (3S):352. (2012) Poster presentation ASTRO 2012
  20. Hashem R\*, Winter K, Ruo R, **Portelance L**, Jhingran A, Demas W, Jacobson GM, Gaffney D. Defining the impact of the use of oral contrast in pelvic intensity modulated radiation therapy (IMRT); An RTOG 0418 secondary analysis. *Int J Rad Onc Biol Phys.* 84(3S): 18. (2012) Oral presentation, gynecological scientific paper, ASTRO 2012
  21. Register S, **Portelance L**, Kwon D, Wolfson A. The role of adjuvant radiation in stage III endometrial cancer. *Int J Rad Onc Biol Phys.* 84(3S):448. (2012) Poster presentation ASTRO 2012
  22. **Portelance L**, Moughan J, Jhingran, A, Miller BE, Salepour RR, D'Souza D, Haddock M, Rotman M, Gaffney DK. A phase II multi-institutional study of postoperative pelvic intensity modulated radiation therapy (IMRT) with weekly Cisplatin in patients with cervical carcinoma: Two year efficacy results of the RTOG 0418. *Int J Rad Onc Biol Phys.* 81(2):3. (2011). Oral presentation research plenary session ASTRO 2011
  23. Wu X, Gupta S, Umar S, Agarwal AK, **Portelance L**, Stoyanova R, Pollack A, Ahmed MM. Space-time Fractionation (STF): A Special Concept Whose Time Has Come. *Int J of Rad Onc • Biol • Phys.* 81(2);750 (2011) **Poster presentation ASTRO 2011**
  24. Jhingran A, Winter K, **Portelance L**, Miller BE, Salepour RR, Gaur R, Souhami L, Small W, Gaffney DK. Efficacy and safety of IMRT after surgery in patients with endometrial cancer: RTOG 0418 phase II study. *Int J Rad Onc Biol Phys.* 81(2):45. (2011) Oral presentation, gynecological scientific paper, ASTRO 2011
  25. Iglesias, AI, Wolfson AH, Portelance L, Zhao W, Stine J, Yali P, Lucci J, Schuman S. Adjuvant vaginal brachytherapy and chemotherapy in the management of high-intermediate risk early-stage endometrial cancer: A single institutional report. *Int J Radiat Oncol Biol.* 81(2):476 (2011) Poster presentation ASTRO 2011
  26. Kopek, N, **Portelance, L**, Rajakesari S, Parker W, Evans M, Ruo R, Comeau L, Faria S; Brachytherapy versus Tomotherapy versus Stereotactic Body Radiotherapy (SBRT) for the delivery of a rectal boost: a comparative dosimetric study ECCO (2011) Poster presentation, ECCO 2011
  27. Rajakesari S\*, **Portelance L**, Kopek N, Parker W, Evans M, Comeau L, Ruo R, Faria S. A dosimetric comparison of brachytherapy versus tomotherapy versus stereotactic body radiotherapy (SBRT) for the delivery of a rectal tumor boost. *Int J Rad Onc Biol Phys.* 81(2):370. (2011) Poster presentation ASTRO 2011
  28. Iglesias A.J, Wolfson A.H, **Portelance L**, Zhao W, Stine J, Yali P, Lucci J, Schuman S. Adjuvant vaginal brachytherapy and chemotherapy in the management of high intermediate risk early-stage endometrial cancer: a single institutional report. *Int J Rad Onc Biol Phys.* 81(2): 476. (2011) Poster presentation ASTRO 2011

29. Lim K, Fyles T, **Portelance L**, Creutzberg C, Jurgenliemk- Schulz IM, Viswanathan A, Erickson B, Bosch W. Variability in Clinical Target Volume Delineation for Intensity Modulated Radiotherapy in Three Challenging Cancer Scenarios Int J Rad Onc Biol Phys. 78(3) S155. (2010) Oral presentation gynecology scientific paper ASTRO 2010
30. Gallant F\*, **Portelance L**, Al-Halabi H, Alfieri J, Al-Wassia R, Sultanem K, Cury F. Needs assessment and development of an e-learning module on head and neck anatomy for residents in radiation oncology. Int J Rad Onc Biol Phys. 78(3):155. (2010) Oral poster presentation Head and Neck scientific session ASTRO 2010
31. Klopp A.H., Moughan J, **Portelance L**, Miller B.E, Salehpour M.R, D'Souza D, Souhami L, Small W, Gaur R. Hematologic toxicity on RTOG 0418: A phase II study of post-operative IMRT for gynecologic cancer. Int J Rad Onc Biol Phys. 78(3):121. (2010) Oral presentation gynecology scientific session ASTRO 2010
32. Patil N.G, Pavamani S, Pearce A, D'Souza D.P, **Portelance L**, Khan R, Traptow L, Craighead P.S, Doll C.M. Brachytherapy for cervical cancer: Canadian patterns of practice changes, 2006-2009. Int J Rad Onc Biol Phys. 78(3):141. (2010) Poster presentation ASTRO 2010
33. **Portelance L**, Winter K, Jhingran A, Miller BE, Salehpour MR, De Souza D, Haddock M, Rotman M, Gaffney D. Post-operative intensity modulated radiation therapy (IMRT) with chemotherapy in patients with cervical carcinoma/ RTOG 0418 Phase II Study. Int.J Rad Onc Biol Phys. 75(3):S640 (2009) Poster presentation ASTRO 2009
34. Al-Halabi H, Poon E, **Portelance L**, Duclos M, Souhami L. Comparison between cone beam CT based three dimensional planning and modified monte carlo dose calculation in intracavitary Brachytherapy for cervical cancer. Int J Rad Onc Biol Phys. 75(3): 623. (2009) Poster presentation ASTRO 2009
35. Fyles A, Lim K, Small W, **Portelance L**, Gaffney D, Erickson B, de Los Santos J, Ishikam S, Creutzberg C, Bosch W. Variability in Delineation of Clinical Target Volumes for Cervix Cancer Intensity-modulated Pelvic Radiotherapy. Int J Rad Onc Biol Phys. 75(3):83. (2009) Oral presentation gynecology scientific session ASTRO 2009
36. Alfieri J\*, Steinert Y, McLeod M, **Portelance L**. Evaluation of a web-based learning module for radiologic anatomy and radiotherapy treatment planning. Int J Rad Onc Biol Phys. 75(3): 84. (2009) Poster presentation ASTRO 2009
37. Alfieri J\*, Steinert Y, McLeod M, **Portelance L**. Results of a randomized controlled trial to assess the efficacy of a web-based learning module for radiologic anatomy and radiotherapy treatment planning. Radiother and Oncol.(2009) Oral presentation CARO 2009  
Best resident research award
38. Alfieri J\*, **Portelance L**, Steinert Y, McLeod P. The effectiveness of web-based anatomy instruction in radiation oncology. Canadian Conference on Medical Education (Edmonton) May 2-6 (2009) Poster presentation
39. Wan J, Cohen V, Agulnik J, Faria S, **Portelance L**, Ofiara L, Sultanem K, Souhami L, Hirsh V. Unexpected High Lung Toxicity from Radiation Pneumonitis in a Phase I/II Trial of Concurrent Erlotinib with Limited Field Radiation for Intermediate Prognosis Patients with

Stage III or Inoperable Stage IIB Non–small-cell Lung Cancer(NSCLC) Int J Rad Onc Biol Phys 75(3):110 (2009) Poster presentation ASTRO 2009

40. Jhingran A, Winter K, **Portelance L**, Miller B, Salehpour M, Gaur R, Souhami L, Small W, Berk L, Gaffney D. A Phase II study on Intensity Modulated Radiation Therapy (IMRT) to the pelvis for Post-operative Patients with Endometrial Carcinoma (RTOG0418). Int J Rad Onc Biol Phys. 72(1):S16-17 (2008) Oral presentation ASTRO 2008
41. Al-Halabi H\*, **Portelance L**, Souhami L, Duclos M, Bahoric B, Reniers B. The use of Cone beam CT Based Three-Dimensional Planning in intracavitary Brachytherapy for Cervical Cancer. International Gynecological Cancer Society (IGCS) Annual Meeting, Bangkok (2008) Poster presentation IGCS 2008
42. Portelance L, El Sheshtawy W, Souhami L, Duclos M, Bahoric B, Gilbert L, Stanimir G, Legler C, Strugeon J, Arsenault L. Concurrent chemo-radiation therapy combined with hypofractionated high dose rate Brachytherapy for patients with locally advanced cervical cancer. McGill experience. International Gynecological Cancer Society (IGCS) Annual Meeting, Bangkok, October (2008) Poster presentation IGCS 2008
43. Al-Halabi H, **Portelance L**, Reniers B, Bloemers M, Duclos M, Niazi T, Bahoric B, Souhami L. The use of Cone Beam CT Based Three-Dimensional; Planning in Intracavitary Brachytherapy for Cervical Cancer. Int J Rad Onc Biol Phys. 72(1):583. (2008) Poster presentation ASTRO 2008
44. Al-Halabi H, **Portelance L**, Reniers B, Bloemers M, Duclos M, Niazi T, Bahoric B, Souhami L. The use of Cone Beam CT Based Three-Dimensional; Planning in Intracavitary Brachytherapy for Cervical Cancer. Radiother and Oncol.(2008) Poster presentation CARO 2008
45. Bloemers M\*, **Portelance L.**, Chao R., Duclos M., Bahoric B., Souhami L., A Dosimetric Analysis of Intensity Modulated Radiation Therapy (IMRT) Versus 3D Conventional Radiation in Vulvar Cancer. Int J Rad Onc Biol Phys. 72(1): 362-363. (2008) Poster presentation ASTRO 2008
46. Bloemers M\*, **Portelance L.**, Chao R., Duclos M., Bahoric B., Souhami L. The use of pelvic intensity modulated radiation therapy (IMRT) for patients with vulvar cancer. (2008) Poster presentation CARO 2008
47. Patone H, Souhami L, Parker W, Evans M, Duclos M, **Portelance L**. A dosimetric comparison of two High-Dose-Rate Brachytherapy Planning Systems in Cervix Cancer: Standardized template planning versus Computerized Treatment Planning. ABS/ GEC-ESTRO World Congress of Brachytherapy (WCB) Bi Annual Meeting. (2008) Poster presentation WCB 2008
48. Al Refae MA, Roberge D, **Portelance L**, Gilbert L. Endometrial carcinoma in elderly women : Disease Outcome and Treatment Morbidity. Int J Rad Onc Biol Phys. 69(3):S397-398. (2007) Poster presentation ASTRO 2007
49. Gaffney D, Du Bois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, **Portelance L**,

- Sadoyze A, Poetter R, Colombo A, Randall M, Mirza M.R. Trimble E.L. Radiotherapy practice in vulvar cancer among member groups of the gynecologic cancer intergroup (GCIG) (2007) Poster presentation ESGO meeting in Berlin
50. Vuong T, **Portelance L**, Ruo R, Cury F, Alcindor T, Stein B, Charlebois P, Dalfen R, Meterissian S, Wexler M. A Dose Escalation Phase II Study Using Intensity Modulated Radiation Therapy (IMRT) to Deliver Preoperative 60 Gy in 25 fractions with 5-Fluorouracil Chemotherapy to Patients with T4 Rectosigmoid Cancer. *Int J Rad Onc Biol Phys.*66 (3):.270. (2006) Poster presentation ASTRO 2006
51. Vuong T, Ducruet T, Kopek N, Portelance L, Bahoric B, Devic S. Conformal therapy as a mean to improve treatment therapeutic index for patients with anal canal cancer *Radiother and Onc* 78(1): 37-38 (2006) Poster presentation ESTRO 2006
52. Patone H, **Portelance L**, Parker W, Souhami L. A comparison of Individualized Treatment Planning (ITP) to a Standardized Template Planning (STP) Approach in High Dose Rate Brachytherapy (HDRB) for Cervix Cancer (Cxca), *Radiother and Oncol.* 80(S1):223 (2006) Poster presentation CARO 2006
53. Patone H, **Portelance L**, Parker W, Souhami L. A dosimetric comparison of two high dose rate Brachytherapy Planning System in Cervix Cancer: Individualized Treatment Planning Versus Standardized Template Planning. *Int J Rad Onc Biol Phys.* 66(3): 400-401. (2006) Poster presentation ASTRO 2006
54. Faria S, Lisbona R, Stern J, Souhami L, **Portelance L**, Devic S, Freeman C. Pre and Post-Treatment PETCT to evaluate the Response of Non-Small Cell Lung Cancer (NSCLC) Treated with Curative Radiotherapy Alone (RT). *Radiother and Oncol.* 80(S1):172. (2006) Poster presentation CARO 2006
55. Vuong T, Lisbona R, Artho G, Waschke K, Richard C, Stein B, Charlebois P, Loungnarath R, **Portelance L**, Reinhold C. A Prospective study to evaluate the value of positron emission computerized tomography (PET CT) in the primary management of patients with newly diagnosed rectal cancer. (2006) Oral presentation ESTRO 2006
56. Hirsh V, Duclos M, Souhami L, DelVecchio P, Ofiara L, Faria S, Ayoub JP, Charpentier D, Portelance L, Soulieres D. Phase II Trial with Carboplatin/Gemcitabine (CB/G) Induction Chemotherapy Followed by Radiotherapy Concomitantly with Paclitaxel/ Gemcitabine (P/G) in Stage III A+B Non-Small Cell Lung Cancer (NSCLC): Final report. *JCO* 24(18): 7139. (2006)
57. Small W, Gaffney D, **Portelance L**. Practice patterns of radiotherapy in endometrial cancer among member groups of the gynecologic cancer intergroup (GCIG) Biennale International Gynecologic Cancer Society Meeting, Santa Monica, (2006) Poster presentation GCS 2006
58. N. Kopek, T. Vuong, **L. Portelance**, B. Bahoric, S. Devic, The impact of conformal therapy in the treatment of patients with anal canal cancer, *Eur. J. Cancer* 3(S2): 733 (2005). Poster presentation ESTRO 2005
59. Vuong T, Kopek N, **Portelance L**, Bahoric B, Sultanem K, Devic S. Conformal therapy improves the therapeutic index in patients treated with radiation therapy and concurrent

- chemotherapy for anal cancer. J of Clin Oncol. 23(16S): 258. (2005). Poster presentation ASCO GI 2005
60. Alfieri J\*, **Portelance L**, Huang F, Souhami L. Development of a Web Based Anatomy Teaching Module for the Radiation Oncology Residents. A pilot. Int J Rad Onc Biol Phys. 63(S1):S347. (2005) Poster presentation ASTRO 2005
61. Aslani M, Faria S, Tafazoli F, Duclos M, **Portelance L**, Guerra J, Freeman C. Does RTOG/EORTC Scoring Schema (RESS) Truly Reflect the Late Radiation Morbidity in Lung Cancer Patients. Int J Rad Onc Biol Phys. 63(S1):S393-394. (2005) Poster presentation ASTRO 2005
62. Patel S, Gilbert L, Schwartz M, **Portelance L**, Stanimir G, Souhami L. Predictors of Outcome and patterns of Failure in Patients with Pathologic Stage III Endometrial Cancer Confined to the Pelvis. Int J Rad Onc Biol Phys. 63(2):212. (2005) Poster presentation ASTRO 2005
63. Patel S, Gilbert L, **Portelance L**, Stanimir G, Souhami L. Analysis of prognostic Factors and Patterns of Recurrence in Patients with Pathologic Stage III Endometrial Cancer Confined to the Pelvis. Radiother and Oncol. 76(S1):64. (2005) Poster presentation CARO 2005
64. Alfieri J, **Portelance L**, Huang F, Souhami L. Development of a web based anatomy teaching module for the radiation oncology residents. Radiother and Oncol. 76(S1):64. (2005) Poster presentation CARO 2005
65. **Portelance L**, Parker W. Development of Individualized Teaching Interventions Through Use of Web CT Physics Teaching Modules for Radiation Oncology Residents. Radiother and Oncol. 76(S1):52. (2005) Poster presentation CARO 2005
66. Vuong T, **Portelance L**, Ruo R, Dalfen R, Meterissian S, Stein B, Gouttebel MC, Wexler M. Neoadjuvant chemotherapy and radiation with intensity modulated radiation therapy (IMRT) in a dose escalation phase II study for patients with T4 rectosigmoid cancer. Radiother and Oncol. 76(S1): 3. (2005) Oral presentation CARO 2005
67. Niazi M, Faria S, Chen M, Souhami L, Duclos M, **Portelance L**, Guerra J, Hirsh V, Ofiara L, Freeman C. 10 year experience with small cell lung cancer (SCLC)- limited stage (LS) at the McGill University Health Centre. Radiother and Oncol. 76(S1):56. (2005) Poster presentation CARO 2005
68. Faria S, Souhami L, Duclos M, **Portelance L**, Guerra J, Devic S. Preliminary Results with Hypofractionated Radiation Therapy (HRT) Alone as the Curative Treatment for Patients with Early Stage, Medically Inoperable Non-Small Cell Lung Cancer (NSLC). Radiother and Oncol. 76(S1): 21. (2005) Oral presentation CARO 2005
69. Patel S, **Portelance L**, Arseneau J, Stanimir G. Adjuvant Radiation Therapy and High Dose Rate Brachytherapy for pathologic Stage III Endometrial Cancer. JCO 23(16S): 5157 (2005)
70. Kopek N, Vuong T, **Portelance L**, Bahoric B, Sultanem K, Devic S. Long term Follow Up Results of Conformal Therapy for Patients with Anal Cancer. Radiother and Oncol. 76(S1):65. (2005) Poster presentation CARO 2005

71. Faria S, Souhami L, **Portelance L**, Duclos M, Vuong T, Small D, Freeman CR. Hypofractionated radiation therapy (HRT) alone as the curative treatment for patients with early stage inoperable non-small cell lung cancer (NSCLC) Lung Cancer. 49(2):306-7. (2005) Poster presentation International Lung Cancer Meeting 2005
72. Gagnon B, Mayo N, Sirois C, **Portelance L**, Mihalciou C, O'Fiara L. Improving quality of life of patients with lung cancer: Time for a paradigm shift. Lung Cancer.49(S2):S335 (2005)
73. Hirsh V, Soulieres D, Duclos M, DelVecchio P, Ofiara L, Ayoub JP, Faria S, **Portelance L**, Charpentier D, Souhami L. Phase II trial with carboplatin/gemcitabine (Cb/G) induction chemotherapy (CT) followed by radiotherapy concomitantly with paclitaxel/gemcitabine (P/G) in Stage III non-small cell lung cancer (NSCLC), Lung Cancer. 49(S2):169 (2005)
74. Vuong T, Kopek N, **Portelance L**, Bahoric B, Devic S. Conformal therapy improves the therapeutic index in patients treated with radiation therapy and concurrent chemotherapy for anal cancer. ASCO GI meeting proceedings JCO Abstract 186. (2005) Poster presentation ASCO GI 2005
75. Hirsh V, Duclos M, DelVecchio P, Ofiara L, Ayoub JP, Faria S, Charpentier D, **Portelance L**, Souhami L, Soulieres D. Phase II Trial with Carboplatin/Gemcitabine (CB/G) Induction Chemotherapy Followed by Radiotherapy Concomitantly with Paclitaxel/ Gemcitabine (P/G) in Stage III A+B Non-Small Cell Lung Cancer (NSCLC). JCO. 23(16): 7122 (2005)
76. Duclos M, Hirsh V, Soulieres D, DelVecchio P, Ofiara L, Ayoub J, Faria S, **Portelance L**, Souhami L. Phase II trial with Carboplatin/Gemcitabine induction chemotherapy followed by radiotherapy concomitantly with Paclitaxel/Gemcitabine in Stage III Non-Small Cell Lung Cancer. Int J.Rad. Onc. Biol. Phys. 63(S1):S399 (2005) Poster presentation ASTRO 2005
77. Vuong T, Meterissian S, Ruo R, Dalfen R, **Portelance L**, Wexler M, Stein B, Charlebois P, Gouttebel MC, Falco T. Neoadjuvant chemotherapy and radiation with intensity modulated radiation therapy (IMRT) in a dose escalation Phase I/II study for patients with T4 rectosigmoid cancer. ASCO GI meeting proceedings. JCO Abs S3 (2005) Poster presentation ASCO GI 2005
78. Souhami L, Patel S, **Portelance L**, Gilbert L, Stanimir G. Predictors of toxicity in Stage III endometrial Cancer Treated with External-Beam Radiotherapy, Réunion Annuelle de la Société Européenne de Radio-Oncologie, Paris. (2005) Poster presentation
79. Faria S, Souhami L, Duclos M, Portelance L, Guerra J, Devic, F. DeBlois, D. Small, Gruber J, Freeman CR. Accelerated hypofractionation for early stage non-small cell lung cancer (NSCLC): results of patients treated with 3D conformal radiotherapy alone. Eur. J. Cancer. 3(S2):1145. (2005). Poster presentation ESTRO 2005
80. Faria S, Souhami L, Duclos M, **Portelance L**, Vuong T, Freeman C. Accelerated Hypofractionation Three Dimensional Conformal External Beam Radiation Therapy (3DCRT) in patients with early stage but medically inoperable Non-Small-Cell Lung Cancer (NSCLC): Early Results. Radiother and Oncol.72 (S1) Abs 50 (2004) Poster presentation CARO 2004
81. Niazi TM, Souhami L, **Portelance L**, Bahoric B. High Dose Rate Brachytherapy (HDRB) for Selected Patients with Stage I endometrial carcinoma Radiother and Oncol. 73(S1):S239 (2004) Poster presentation CARO 2004

82. Patel S, Vuong T, Ballivy O, **Portelance L**, Parker W, Patrocinio H. Phase II trial of pelvic intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy for patients with rectal cancer. *Radiother and Oncol.* 73(S1):263 (2004) Poster presentation CARO 2004
83. Faria S, Souhami L, Duclos M, **Portelance L**, Vuong T, Freeman C. Accelerated Hypofractionation Three Dimensional Conformal External Beam Radiation Therapy (3DCRT) in patients with early stage but medically inoperable Non-Small-Cell Lung Cancer (NSCLC): Early Results. *Radiother and Oncol.* 72 (S1) Abs 50 (2004) Poster presentation CARO 2004
84. Faria S, Souhami L, Duclos M, **Portelance L**, Vuong T, Freeman C. Acute toxicity with accelerated hypofractionation three-dimensional conformal external beam radiation therapy (3DCRT) in patients with early stage but medically inoperable Non-Small-Cell Lung Cancer (NSCLC). *European Society of Therapeutic Radiation Oncology (ESTRO), Amsterdam (2004)* Poster presentation
85. Vuong T, Parent J, **Portelance L**. Preoperative High Dose Rate Endorectal Brachytherapy (HDREBT) as an Alternative to Chemotherapy (CT) and External Beam Radiation (ERT) for locally Advanced Rectal Cancer. *Radiother and Oncol.* 72(S1): S294 (2004) Poster presentation CARO 2004
86. Niazi TM, Souhami L, **Portelance L**, Bahoric B. High Dose Rate Brachytherapy (HDRB) as an Alternative to Surgery in Selected Patients With Stage I Endometrial Carcinoma. *Radiother and Oncol.* 72 (S1):108 (2004) Poster presentation CARO 2004
87. Niazi TM, Souhami L, Stanimir G, **Portelance L**, Bahoric B. Can high Dose Rate Brachytherapy be an Alternative to Surgery in Selected Patients with Stage I Endometrial Carcinoma. *Int J Rad Onc. Biol. Phys.* 60(S1): S307 (2004) Poster presentation ASTRO 2004
88. Niazi T.M., Souhami L, **Portelance L**, Bahoric B. High Dose Rate Brachytherapy (HDRB) for Selected Patients with Stage I endometrial carcinoma *Radiotherapy and Oncology. ESTRO, Amsterdam (2004)* Poster presentation ESTO 2004
89. Patel S, Vuong T, Ballivy O, **Portelance L**, Parker W, Patrocinio H. Intensity Modulated Radiotherapy (IMRT) Reduces Acute Toxicity in the treatment of Rectal Cancer: Results of a Phase II Study. *Radiother and Oncol* 72(S1):109 (2004) Poster presentation CARO 2004
90. Patel S, Vuong T, Ballivy O, **Portelance L**, Parker W, Patrocinio H. Intensity Modulated Radiotherapy (IMRT) Reduces Acute Toxicity in the treatment of Rectal Cancer: Results of a Phase II Study. *Int J Rad Onc Biol Phys.* 60(S1): S424-425 (2004) Poster presentation ASTRO 2004
91. Patel S, Vuong T, Ballivy O, **Portelance L**, Parker W, Patrocinio H. Phase II trial of pelvic intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy for patients with rectal Cancer. *ESTRO, Amsterdam (2004)* Poster presentation
92. Vuong T, Franco E, Lambert C, **Portelance L**, Nasr E, Faria S, Hay J, Larson S, Shenouda G, Souhami L, Wong F, Freeman C. Effective prevention of radiation induced dermatitis with silver leaf dressing during concurrent chemotherapy and radical radiation on the perineum: results of a phase II study using multiple blinded observers to score end of

treatment photographs. Radiother and Oncol. 69(S1):34 (2003) Oral presentation CARO 2003

93. Shenouda G, Belenkov L, Souhami L, Duclos M, **Portelance L**, Chow T. Erythropoietin receptor expression and the in-vitro effect of erythropoietin on the radiation response of different cancer cell lines. Radiother and Oncol. 69 (S1), Abs 41 (2003) Oral presentation CARO 2003
94. **Portelance L**, Chao C, Grigsby PW, Bennet H. Intensity modulated radiation therapy (IMRT) could reduce small bowel, rectum and bladder complications in patients with cervical cancer treated to the pelvis and para-aortic nodes Int J Rad Onc Biol and Phys. 45(3): 211 (1999) Oral presentation ASTRO 1999
95. **Portelance L**, Grigsby P.W. The use of a cervical ring applicator to stop bleeding in cervix cancer. American Brachytherapy Society Annual Meeting, San Francisco (1999) Poster presentation ABS 1999
96. **Portelance L**, Gyger M, Chabot P, Roy D. Disease free survival advantage conferred by post-transplant irradiation in patients with Non-Hodgkin's Lymphoma treated by High Dose Chemotherapy and progenitor cell transplantation. Clin Invest Med 20 (4) (1997) Poster presentation CARO 1997
97. **Portelance L**, Gyger M. Prognostic factors in patients with Non-Hodgkin Lymphoma treated with high dose chemotherapy and stem cell rescue. French Society of Radiation-Oncology, Paris. (1997) Poster presentation SFRO 1997

## 21. Other Works Accepted for Publication:

1. Hall W, Heerkens D, Paulson E.S., Meijer G.J., , Kotte A.N., Knechtges P, Parikh P.J., Bassetti M.F., Lee P., Aitken K.L., Palta M., Myrerhaug S., Koay E.J., **Portelance L.**, Ben-Josef E. Erickson B.A. Pancreatic Adenocarcinoma Gross Tumor Volume Contouring On Computed Tomography (CT) as Compared to Magnetic Resonance Imaging (MRI) Results Of An International Consensus Contouring Conference. Will be published in IJROBP proceedings 2017. Accepted for poster presentation ASTRO 2017.
2. Ramey S.J., Kwon D., Mellon E.A, Wolfson A.H., **Portelance L.**, Yechieli R. Ethnic and Racial Disparities in Delay of Definitive Chemoradiation for Anal Cancer: A National Analysis Will be published in IJROBP proceedings 2017. Accepted for poster presentation ASTRO 2017
3. Ramey S.J., Kwon D., Mellon E.A, Wolfson A.H., Yechieli R., **Portelance L.** Ethnic and Racial Disparities in Delay of Definitive Chemoradiation for Cervical Cancer: A National Analysis. Will be published in IJROBP proceedings 2017. Accepted for poster presentation ASTRO 2017

**V. Professional****22. Funded Research Performed****Project Title:** High Performance Site Initiatives**Role:** Institution Principal Investigator**Funding Agency:** NIH NCI**Amount:** \$70 400**Funding Period:** April 2017-present**Brief Description:** University of Miami has been selected by the NCTN Leadership Committee to participate in the High Performance Site Initiative (HPSI). We have financial aid to support the infrastructure to enable continued participation on NCTN studies. I have been selected to coordinate/facilitate HPSI payments for our site (letter attached to submission).**Project Title:** A Phase III clinical trial evaluating the efficacy and safety of TheraSphere in patients with metastatic colorectal carcinoma to the liver who have failed first line chemotherapy.**Principal Investigator:** Mary F Mulcahy, MD; Northwestern University

Ricky Sharma, MA FRCP FRCR PhD; University of Oxford

**Role:** Institution Principal Investigator**Funding Agency:** BTG Biocompatibles International (Grant number:TS102)**Amount:** Per case funding**Funding Period:** 03/2016-03/2020**Brief Description:** The objective of this study is to evaluate the efficacy and safety of TheraSphere in patients with metastatic colorectal cancer of the liver who have progressed with first line chemotherapy**Project Title:** NRG Collaborative group member agreement**Principal Investigator:** Walter Curran, MD; Emory University**Role:** Institution Principal Investigator NRG**Funding Agency:** NIH/NCI (Grant number: U10CA180868)**Amount:** Per case funding \$2000.case**Funding Period:** 04/2014-02/2019**Brief Description:** NRG is a research consortium formed in 2014 from the fusion of GOG, NSABP and RTOG. Our institution has enrolled more than 25 patients on NRG clinical trials last year and therefore has a full member status**Project Title:** Effectiveness of Image Guided (IG) Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Cervix Cancer**Principal Investigator:** Loren Mell, MD; UCSD**Role:** Institution Principal Investigator**Funding Agency:** UCSD Clinical Trial (Grant number: #80461356)**Amount:** \$50 000**Funding Period:** 06/2016-06/2020**Brief Description:** This is a randomized control trial for patients with locally advanced cervix

cancer looking at the efficacy of bone marrow sparing intensity modulated radiation therapy (IMRT) versus institution standard pelvic radiation approach

**Title:** RTOG Collaborative group agreement

**Principal Investigator:** Walter Curran, MD; Emory University

**Role:** Institution PI Radiation Therapy Oncology Group (RTOG)

**Funding Agency:** NIH NCI

**Amount:** Per case funding \$1800 /case

**Funding Period:** 01/2011-03/2014

**Brief Description:** The Radiation Therapy Oncology Group (RTOG) is a clinical trial collaborative group initially organized in 1968 as a national clinical cooperative group for the purpose of conducting radiation therapy research and cooperative clinical investigations. Funding from the National Cancer Institute began in 1971. The RTOG activated over 500 protocols, accrued more than 110,000 patients to cooperative group studies.

**Title:** RTOG 0848 A Phase III Trial Evaluating both Erlotinib And Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

**Principal Investigator:**

**Role:** Site Principal Investigator, University of Miami

**Funding Agency:** NIH NCI

**Amount:** Per case funding \$2000/ case

**Funding Period:** 11/2011-present

**Brief Description:** This is a randomized control trial for patients who underwent Whipple surgery for head of the pancreas cancer. Patients are randomized to adjuvant chemotherapy +/- radiation

**Title:** NCIC EN-7, A Randomized Trial of Adjuvant Pelvic Radiation Versus Adjuvant Pelvic Radiation Combined with Chemotherapy in the Treatment of Patients with High Risk Endometrial Cancer (Portec 3)

**Principal Investigator:** International: Carien L. Creutzberg, MD, PhD; Leiden University

Canadian: Tony Files, MD; Toronto University

**Role:** Site Principal Investigator, McGill University

**Funding Agency:** NCIC

**Amount:** Per case funding \$1800 /case

**Funding Period:** 06/2009-09/2010

**Brief Description:** The National Cancer Institute in Canada endorsed this Deutsch trial randomizing patients with high risk endometrial cancer to adjuvant radiation therapy + - chemotherapy.

**Title:** Phase 2 clinical trial on a multidisciplinary approach for the treatment of patients diagnosed with rectal cancer and synchronous resectable liver metastases

**Role:** Principal Investigator

**Funding Agency:** Sanofi Research Grant

**Amount:** \$80,000

**Funding Period:** 9/2009-9/2010

**Brief Description:** This is a Phase 2 clinical trial I designed for patients with Stage IV rectal cancer with oligo metastatic disease, limited to the liver. The trial included a multidisciplinary

approach combining chemotherapy, radiation and surgery to offer a curative treatment to this selected patients population.

**Title:** Grant received for the development of a Web-Based teaching module on Head and Neck Anatomy for Radiation Therapy Residents.

**Role:** Principal Applicant

**Funding Agency:** McGill Teaching and Learning Improvement Fund (TALIF)

**Amount:** \$12,000

**Funding Period:** 05/2006-08/2010

**Brief Description:** This project was to design a web based learning module on the management of head and neck cancer for the radiation oncology residents.

**Title:** RTOG 0417 A Phase II study of Site Principal Investigator Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma

**Principal Investigator:** Tracey Schefter, MD; University of Colorado in Denver

**Role:** Site Principal Investigator McGill University

**Funding Agency:** NIH NCI

**Amount:** Per case funding \$1800/ case

**Funding Period:** 09/2006-8/2009

**Brief Description:** This was a single arm phase II study designed to look at the effect of adding Bevacizumab to the standard chemoradiation regimen for the management of patients with locally advanced cervical cancer.

**Title:** RTOG 0418 A phase II Study of Intensity Modulated Radiation Therapy. (IMRT) to the Pelvis +/- Chemotherapy for Post-Operative Patients with Either Endometrial or Cervical Carcinoma

**Principal Investigator:** Anuja Jhingran, MD; MD Anderson Cancer Center

Lorraine Portelance, MD; McGill University

**Role:** National Co-chair and Institution Principal Investigator McGill University

**Funding Agency:** NIH NCI

**Amount:** Per case funding \$1800/ case

**Funding Period:** 03/2006-11/2008

**Brief Description:** This phase II study was designed to prove the feasibility of doing a multicentric clinical trial using intensity modulated radiation therapy (IMRT) to deliver pelvic radiation for patients with either cervical or endometrial cancer who underwent surgery.

**Title:** A phase III study to evaluate the value of silver leaf dressing in preventing radiation dermatitis for patients undergoing chemotherapy and external radiation to the perineum

**Principal Investigator:** Te Vuong, MD; McGill University

**Role:** Co-applicant

**Funding Agency:** National Cancer Institute of Canada, CCS Research Grant

**Amount:** \$128,000

**Funding Period:** 05/2005-12/2008

**Brief Description:** Patients diagnosed with anal canal, vulvar or low rectal cancer were randomized on this clinical trial comparing standard of care versus silver leaf to prevent dermatitis caused by radiation therapy to the genitals area.

**Title:** RTOG 0214 Randomized Study on the Use of Prophylactic Brain Irradiation for Patients with Non-Small Cell Lung Cancer

**Principal Investigator:** Elizabeth M. Gore, MD. Milwaukee Regional Medical Center

**Role:** Site Principal Investigator, McGill University

**Funding Agency:** NCI NIH

**Amount:** Per case funding \$1800/ case

**Funding Period:** 01/2003-08/2007

**Brief Description:** This RTOG clinical trial was designed to define the benefit of whole brain radiation delivered to prevent brain metastasis in patients diagnosed with non-small cell lung.cancer;

**Title:** RTOG 0116 A Two-Part Phase I/II Study of Extended Field External Irradiation and Intracavitary Brachytherapy Combined with Chemotherapy (weekly Cisplatin-Arm 1) and Amifostine (weekly Cisplatin and Amifostine- Arm 2) in Carcinoma of the Cervix with Positive Para-Aortic or High Common Iliac Lymph Nodes

**Principal Investigator:** William Small Jr., M.D. Northwestern Memorial Hospital

**Role:** Site Principal Investigator, McGill University

**Funding Agency:** NCI NIH

**Amount:** Per case funding

**Funding Period:** 09/2003-03/2007

**Brief Description:** Prospective randomized clinical trial of extended field external beam radiation with concomitant chemotherapy +/- Amifostine for the management of patients with locally advanced cervical cancer

**Title:** The value of Botox in acute radiation proctitis- A phase I/II study

**Principal Investigator:** Te Vuong, M.D; McGill University

**Role:** Co-applicant

**Funding Agency:** Canderel New Initiative Award, McGill University

**Amount:** \$15,000

**Funding Period:** 10/2005-10/2006

**Brief Description:** A phase I/II study assessing the value of Botox injection in the rectal wall post endorectal brachytherapy to control symptoms caused by post treatment rectitis

**Title:** RTOG 0241 Phase I Study of Irinotecan and Cisplatin in Combination with Twice Daily Thoracic Radiotherapy (45Gy) or Once Daily Thoracic Radiotherapy

**Principal Investigator:** Corey J. Langer, MD; Fox Chase Cancer Center

**Role:** Site Principal Investigator, McGill University

**Funding Agency:** NIH NCI

**Amount:** Per case funding \$1800/case

**Funding Period:** 09/2003-06/2006

**Brief Description:** A phase I study on which patients diagnosed with small cell lung cancer, limited stage disease were randomized to once daily or twice daily radiation treatment combined with standard chemotherapy.

**Title:** RTOG 0315 A Randomized, Double Blind, Placebo-Controlled Phase III Study to Determine the Efficacy of Sandostatin LAR Depot (octreotide acetate) in Preventing or Reducing the Severity of Chemoradiation-Induced Diarrhea in Patients with Anal or Rectal Cancer

**Principal Investigator:** Babu Zachariah, MD; University of South Florida Moffitt Cancer Center

**Role:** Site Principal Investigator, McGill University

**Funding Agency:** NIH NCI

**Amount:** Per case funding \$1800 case

**Funding Period:** 05/2005-03/2006

**Brief Description:** A national collaborative group randomized, double Blind, Placebo-Controlled Phase III Study which was designed to determine the efficacy of an octreotide acetate in preventing or reducing the severity of chemoradiation-induced diarrhea in patients with anal or rectal Cancer

**Title:** Pre-operative high dose rate Brachytherapy in preparation for sphincter preservation surgery for patients with advanced cancer of the lower rectum.

**Principal Investigator:** Te Vuong, MD; McGill University

**Role:** Co-applicant

**Funding Agency:** National Cancer Institute of Canada, CCS Research (Grant Number:015127)

**Amount:** \$250,000

**Funding Period:** 04/2004-04/2007

**Brief Description:** A phase II clinical trial for patients diagnosed with locally advanced rectal cancer, offering a short course of endorectal brachytherapy followed by surgery instead of standard chemoradiation therapy.

**Title:** Development of a Radiation Physics Computer Based Learning Module

**Role:** Principal Applicant

**Funding Agency:** McGill Teaching and Learning Improvement Fund (TALIF)

**Amount:** \$6,800

**Funding Period:** 4/2004-4/2005

**Brief Description:** This grant was received to support the development of a computer based dosimetry learning module for residents in radiation oncology.

**Title:** Protocol EPO-CAN-15: "A randomized, double-blind placebo controlled study to evaluate the impact of maintaining hemoglobin levels using EPREX (Epoetin alfa) in limited disease small cell lung cancer (LD SCLC) patients receiving combined chemotherapy and radiation therapy." (The LEGACY Trial)

**Role:** Site Principal Investigator; Centre Hospitalier des Valleees de l'Outaouais (CHVO), Gatineau, QC, Canada

**Funding Agency:** Ortho Biotech

**Amount:** Per case funding \$2400/ case

**Funding Period:** 2001-2002

**Brief Description:** Prospective randomized clinical trial of chemoradiation therapy +/- Eprex in the management of limited disease small cell lung cancer.

**Title:** PCS IV Randomized Control Trial on Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers, three years versus eighteen months

**Principal Investigator:** Abdenour Nabid, MD; Sherbrooke University

**Role:** Site Principal Investigator, Centre Hospitalier des Valleees de l'Outaouais (CHVO)

**Funding Agency:** Astra Zeneca

**Amount:** Per case funding \$800/ case

**Funding Period:** 2001-2001

**Brief Description:** Prospective randomized clinical trial of 18 months versus three years of androgen blockage for patient with high risk prostate cancer

**Title:** PCS III Quebec Provincial study for patients with intermediate risk prostate cancer

**Principal Investigator:** Abdenour Nabid MD, Sherbrooke University

**Role:** Site Principal Investigator, Centre Hospitalier des Valleees de l'Outaouais (CHVO).

**Funding Agency:** Astra Zeneca

**Amount:** Per case funding \$800/case

**Funding Period:** 2001-2002

**Brief Description:** Prospective randomized clinical trial of dose escalation pelvic radiation therapy versus standard dose of radiation combined with hormonal therapy for patients with intermediate risk prostate cancer.

#### **Other Research Not Funded**

**Title:** Multidisciplinary Databank for Patients Diagnosed and Treated with Cervical Cancer in one of the University of Miami Hospital

**Role:** Principal Investigator

**Research Period:** 01/2014-present

**Brief Description:** Retrospective and prospective data collection. The information collected includes: demographics, patients related, tumor related, treatment related characteristics and treatment outcomes data (disease control and treatment side effects) are gathered for all patients diagnosed with cervix cancer and treated in one of University of Miami Hospitals.

**Title:** Multidisciplinary Databank for Patients Diagnosed and Treated with Anal Canal Cancer in one of the University of Miami Hospital

**Role:** Principal Investigator

**Research Period:** 06/2013-present

**Brief Description:** Retrospective and prospective data collection. The information collected includes: demographics, patients related, tumor related, treatment related characteristics and treatment outcomes data (disease control and treatment side effects) are gathered for all patients diagnosed with anal cancer and treated in one of University of Miami Hospitals.

**Title:** Multidisciplinary Databank for Patients Diagnosed and Treated with Pancreas Cancer in one of the University of Miami Hospital

**Role:** Principal Investigator

**Research Period:** 11/2012-present

**Brief Description:** Retrospective and prospective data collection. The information collected includes: demographics, patients related, tumor related, treatment related characteristics and treatment outcomes data (disease control and treatment side effects) are gathered for all patients diagnosed with cervix cancer and treated in one of University of Miami Hospitals.

**Participation in International and National Research Steering Committees**

|   |           |
|---|-----------|
| Member, International Committee, American Brachytherapy Society (ABS)   | 2016-pres |
| Member, Cervix Steering Committee, NRG Collaborative Research Group   | 2012-pres |
| RTOG Liaison, Cervix and Endometrial Committee;<br>International Gynecological Cancer Study Group (IGCSG)       | 2011-pres |
| Member, Cervix Steering Committee, Gynecology Oncology Group (GOG)  | 2012-2014 |
| Member, Gynecology Working Group Steering Committee<br>Radiation Therapy Oncology Group (RTOG)                  | 2004-2013 |
| Gynecology liaison, Advanced Technology Integration Committee (ATIC)<br>Radiation Therapy Oncology Group (RTOG) | 2004-2013 |
| Member, Cervical Cancer Task Force National Institute of Health (NIH)   | 2007-2012 |
| Auditor, Radiation Therapy Oncology Group (RTOG) Washington University,<br>St Louis MI                          | 09/2012   |
| Member, Quality Assurance Committee and Site Auditor;<br>National Canadian Cancer Institute (NCCI)              | 2008-2010 |
| Member, National Canadian Cancer Institute (NCCI)<br>Cervix Cancer Steering Committee                           | 2007-2010 |
| Invited Participant, State of the Science in Cervical Cancer International Meeting,<br>NIH Bethesda, MD         | 09/2007   |
| Invited Participant, RTOG Study Chair Workshop for Young Investigators.<br>Philadelphia, PA                     | 03/2007   |
| McGill Representative to the Gynecologic Site Disease Committee<br>National Canadian Cancer Institute (NCCI)    | 2006-2010 |

**23. Editorial Responsibilities:**

Reviewer:

Practical in Radiation Oncology (2012-present; completed 20 assignments since the first edition in November 2012)

Brachytherapy (2008-present)

International Journal of Radiation Oncology Biology and Physics (2007- present)

International Journal of Gynecological Cancer (2005-present).

Current Oncology (2002-2012)

Senior Editor, International Journal of Radiation Oncology, Biology and Physics  
Gynecological cancer editor's team (2013-2014)

External Reviewer, Traitement néoadjuvant et adjuvant du cancer de l'endomètre Comité de l'évolution des pratiques en oncologie (CEPO) Quebec Health Ministry Document published in November 2012 (2011)

## 24. Professional and Honorary Organizations:

### Memberships

|   |           |
|---|-----------|
| Member, American Radium Society (ARS)                                   | 2012-     |
| Member, American Brachytherapy Society (ABS)                            | 2001-     |
| Member, American Society for Therapeutic Radiology and Oncology (ASTRO) | 2002-     |
| Member, American College of Radiology (ACR)                             | 1993-     |
| Member, International Gynecologic Cancer Society (IGCS)                 | 2004-2012 |
| Member, Canadian Brachytherapy Group (CBG)                              | 2006-2010 |
| Member, Gynaecology Oncology Canada (GOC)                               | 2009-2010 |
| Member, Canadian Association of Radiation Oncology (CARO)               | 1999-2010 |
| Fellow, Royal College of Physicians and Surgeons of Canada (RCPC)       | 1997-2010 |

### Service to professional organizations

Moderator, View Ray Symposium; American Radium Society (ARS) Annual Meeting; Philadelphia, PA (04/2016)

Moderator and Organizer, Hepatocellular Carcinoma Panel; American Radium Society (ARS) Annual Meeting; Philadelphia, PA (04/2016)

Panel Member, Best Practice Statement, Post-operative pelvic radiotherapy for endometrial cancer; American Society for Radiation Oncology (ASTRO), (2012-2015)

\*Document published in 2015

President Elect, Canadian Association of Radiation Oncology (CARO) (2009-2010)

Quebec Director, Canadian Association of Radiation Oncology (CARO) (2001-2004)

Member, Membership Committee and Nominating Committee, Canadian Association of Radiation Oncology (CARO) (2004-2010)

Abstract reviewer, Gynecology section, American Society for Therapeutic Radiology and Oncology (ASTRO) (2009-2010)

Moderator, Gynecology oral poster presentation session. American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting (2010)

Workshop organizer **Portelance L**, Jolicoeur M, Nguyen TV, David S. Radiation Therapy for the Management of Vulvar Cancer. Canadian Association of Radiation Oncology Annual Meeting, Quebec City, QC, Canada (2009)

Workshop organizer, **Portelance L**, Germain I, De Souza D. Management of Endometrial Cancer to Treat or Not to Treat. Canadian Association of Radiation Oncology Annual Meeting Quebec City, QC, Canada (2009)

Abstract reviewer, Gynecology Scientific Paper. Canadian Association of Radiation Oncology (CARO) (2009)

Workshop organizer, Catton P, **Portelance L**, Niazi T. Providing Feedback to Residents. Canadian Association of Radiation Oncology (CARO) Annual Meeting Montreal, QC, Canada (2008)

Moderator, Gynecology Cancer scientific paper presentation. Canadian Association of Radiation Oncology (CARO) Annual Meeting, Toronto, ON, Canada (2007)

Workshop organizer. **Portelance L**, Jolicoeur M, DeSouza D. Image Guided Brachytherapy for Cervical Cancer. Canadian Association of Radiation Oncology (CARO) Annual Meeting Toronto, ON, Canada (2007)

Continuing Medical Education Officer, Quebec Association of Radiation Oncologists (AROQ) (2000-2002)

### **Service to Government Agencies**

Auditor, Quebec Cancer Control Program Committee, Quebec Ministry of Health (2007)  
Member of a multidisciplinary team which was reviewing hospital based cancer program to assess their compliance to the Quebec Cancer Control program.

Medical Expert, Quebec Provincial Committee on Oncology Practice Evaluation, Quebec Ministry of Health (2003)  
Invited as a medical experts to write guidelines on fractionation regimen for the treatment of breast cancer.

Medical Expert, Quebec Provincial Committee on Oncology Practice Evaluation, Quebec Ministry of Health (2000-2004)  
Invited to be part of a multidisciplinary team to write guidelines for the treatment of lung Cancer

### **25. Honors and Awards:**

Fellow American Society of Therapeutic Radiation Oncology (ASTRO) (2017)

Castle Connelly Top Doctors, Exceptional Women in Medicine (2017)

Best Doctors in America (2012-pres.)

Top Oncologists of America (2012-pres.)

Mimi Dupuis Benjamin McGill; Mc Gill University Health Centre Research Institute Award for two consecutive years (\$10 000/year) (2008-2009)

Teacher of the year McGill University Radiation Oncology Residency Program (2006)

Stewart Fellowship in Research/Clinical Hematology and Oncology; McGill University Health Centre Research Institute Award For three consecutive years (\$10 000/year) (2003-2006)

Best resident presentation, Quebec Radiation Oncologists Association (AROQ) Annual Meeting, Montreal, QC (1997)

## **26. Post-Doctoral Fellowship:**

N/A

## **27. Other Professional Activities:**

### **Visiting Professor**

Invited Professor

Grand round: The Integration of Imaging in the Treatment of Patients with Cervical Cancer Meeting with the radiation oncology residents and Faculties  
Bern University Radiation Oncology Department, Bern, Switzerland (August 05, 2015)

Invited Professor

Grand round: The integration of Imaging in the Radiation Treatment Planning of Patients with Cervical Cancer  
Meeting with the radiation oncology residents  
Centre Hospitalier Universitaire de Quebec (CHUQ), Quebec City, QC, Canada (April 17, 2015)

### **Invited Speaker International Meetings**

Portelance L. Radiation Therapy Combined to Nanoknife in the Management of Patients with Pancreas Cancer. Synergy International Meeting on Interventional Radiology in Oncology. Miami, FL. (November 04, 2016)

Invited Medical Expert Portelance L, Rocha Lima CM, Merchant N Multidisciplinary tumor for the management of Pancreas Cancer. Case Discussion Synergy International Meeting on Interventional Radiology in Oncology. Miami, FL. (November 03, 2016)

Invited Medical Expert, Portelance L, Rocha Lima CM, Medrazo B. Multidisciplinary tumor for the management of Pancreas Cancer. Case Discussion Synergy International Meeting on

Interventional Radiology in Oncology. Miami, FL. (November 03, 2016)

Portelance L. The Role of Radiation Therapy in the Management of Patients with Pancreas Cancer. Synergy International Meeting on Interventional Radiology in Oncology. Miami, FL (November 06, 2015)

Portelance L. Proton Therapy for the Treatment of Pancreas Cancer. Synergy International Meeting on Interventional Radiology in Oncology. Miami, FL (October 16, 2014)

Portelance L. Radiation Therapy in the Management of Pancreas Cancer. How Could We Work in Synergy? Synergy International Meeting on Interventional Radiology in Oncology. Miami, FL (October 19, 2013)

Portelance L. The Role of Radiation Therapy in the Management of Cholangiocarcinoma. Synergy International Meeting on Interventional Radiology in Oncology. Miami, FL (November 9, 2012)

Portelance L. The Role of Radiation Therapy in the Management of Pancreatic Cancer. Synergy International Meeting on Interventional Radiology in Oncology. Miami, FL (November 13, 2011)

Portelance L. New Developments in Radiation Therapy for Gynecological Cancer. Journees Françaises d'Oncologie Medicale (FOM). Lille, France (January 17, 2010)

Portelance L. The Use of Intensity Modulated Radiation Therapy (IMRT) in the Management of Patients with Gynecological Cancer. XVIII Brazilian Congress of Cancerology. Curitiba, Brazil (October 28, 2009)

Portelance L. Magnetic Resonance Imaging Guided Brachytherapy for Gynecological Cancer XVIII Brazilian Congress of Cancerology. Curitiba, Brazil (October 28, 2009)

Portelance L. The Role of Radiation Therapy in the Management of Rectal Cancer. XVIII Brazilian Congress of Cancerology. Curitiba, Brazil. (October 28, 2009)

Portelance L. Palliative Radiation Therapy for Patients with Lung Cancer. International Congress on Care of the Terminally Ill. Montreal, QC, Canada (September 28, 2006)

### **Invited Speaker National Meetings**

Portelance L. The University of Miami Experience with MRI Guided Radiation Therapy. American Society of Therapeutic Radiation Oncology (ASTRO) annual meeting. Invited Speaker Industry Symposium. Boston, MA (September 27, 2016)

Portelance L. The University of Miami Experience with MRI Guided Radiation Therapy Radiosurgery Association Annual Meeting. Invited speaker, Technology Symposium. Orlando, FL (June 16, 2016)

Moderator, Gastro-Intestinal Cancer Session. Sylvester Cancer Center Hypofractionation Workshop. Miami, FL (September 29, 2011)

Portelance L. The Use of Intensity Modulated Radiation Therapy in the Treatment of Cervical

Cancer Canadian Radiation Oncology. Residents Royal College Preparatory Course. Montreal, QC, Canada (February 19, 2010)

Portelance L. Update on the activity of the Gynecological Cancer Workgroup Advanced Technology Image Guided Committee. Radiation Therapy Oncology Group Semi-Annual Meeting; Chicago, IL (June 25, 2009)

Portelance L. Update on the activity of the Gynecological Cancer Workgroup Advanced Technology Image Guided Committee Radiation Therapy Oncology Group Semi-Annual Meeting; New Orleans, LA (January 17, 2009)

Portelance L. Esophageal Cancer Management. Resident's annual refresher course Canadian Association of Radiation Oncology Annual Meeting Montreal, QC, Canada (September 29, 2008)

Portelance L. Update on the active clinical trials of the Gynecology tumor site Advanced Technology Image Guided Committee. Radiation Therapy Oncology Group Semi-Annual Meeting; San Diego, CA (January 18, 2008)

Portelance L. Update on the active clinical trials of the Gynecology Cancer Workgroup Advanced Technology Image Guided Committee. Radiation Therapy Oncology Group Semi-Annual Meeting; Philadelphia, PA (June 23, 2007)

Portelance L. Quality Control in Clinical Trials Using Intensity Modulated Radiation Therapy Radiation Oncologists Committee. National Cancer Institute of Canada, Annual meeting; Toronto, ON, Canada (April 28, 2007)

Portelance, L. McGill Experience with High Dose Rate Brachytherapy for the Treatment of Patients with Cervix Cancer. Canadian Brachytherapy Group Annual Meeting; Calgary, AL, Canada (September 13, 2006)

Portelance L. Update on the active clinical trials of the Gynecology tumor site. Image Guided Radiation Therapy Committee. Radiation Therapy Oncology Group semi-annual meeting; Philadelphia, PA (June 24, 2006)

Portelance L. Update on the active clinical trials of the Gynecology tumor site. Image Guided Radiation Therapy Committee. Radiation Therapy Oncology Group semi-annual meeting; San Diego CA (January 21, 2006)

### **Invited Speaker Local Meetings**

Portelance L. The role of radiation therapy in the management of liver cancer  
Radio embolization for the management of liver cancer. Gerbert User's Workshop; Miami, FL (February 6 and 7, 2015)

Portelance L. Volume Definition for the Treatment of Gastro-Intestinal Malignancies Using Intensity Modulated Radiation Therapy (IMRT). Floridian Radiation Oncologists Association; Key Biscayne, FL (July 16, 2011)

Portelance L. Basic Principles of Radiation Therapy. Quebec Family physician's annual

meeting; Montreal, QC, Canada. (November 16, 2008)

Portelance L. The Role of Intensity Modulated Radiation Therapy in the Treatment of Patients with Gynecological Cancer. Quebec Gynecological-Oncologists Annual Meeting; Quebec City, QC, Canada. (February 16, 2008)

Portelance, L. The Role of Intensity Modulated Radiation Therapy In the treatment of Patients with Gynecological Cancer. Quebec Association of Radiation Oncologists Annual Meeting; Quebec City, QC, Canada (June 10, 2006)

Portelance L. The Role of Radiation Therapy in the Treatment of Gynecological Cancer. Quebec Association of Medical Registrars Annual meeting; Montreal, QC, Canada (April 4, 2005)

Portelance L. Treatment Planning for High Dose Rate Endorectal Brachytherapy Conformal Pre-Operative Endocavitary Treatment for Locally Advanced Rectal Cancer. Rectal Cancer Workshop. McGill University; Montreal, QC, Canada. (November 7, 2005)

Portelance L. Development of a Web Based Teaching Module for Radiation Oncology Residents. Medical Education Rounds Mc Gill University. Montreal, QC, Canada (December 2, 2004)

Portelance L. Innovative Treatment in Rectal Cancer. McGill Cancer Center Annual Colon and Gastro-Intestinal Cancers Conference. Montreal, QC, Canada. (November 17, 2004)

Portelance L. Role of Radiation Therapy in the Treatment of Rectal Cancer. Journée d'oncologie du Québec; Montreal, QC, Canada. (November 12, 2004)

Portelance L. Testicular Cancer and Radiation Therapy, Uro-Oncology Meeting of the Groupe d'Etudes en Oncologie du Quebec; Quebec City, QC, Canada. (October 5, 2002)

Portelance L. Prostate Cancer Management. Quebec Radiation Therapy Technologists Association Annual Meeting. Gatineau, QC, Canada. (November 3, 2001)

Portelance L. Intensity Modulated Radiation Therapy. Quebec Radiation Therapy Technologists Association Annual Meeting, Quebec City, QC, Canada. (May 20, 2000)

Portelance L. Radiosensitization and Radiation Therapy. Quebec Radiation Therapy Technologists Association Annual Meeting. Montreal, QC, Canada. (June 4, 1995)

### **Personnal Professional Development**

Radio Embolization for the Treatment of Primary Liver Cancer Advanced Users Meeting. Chicago, IL. (December 2016)

American Society of Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Boston MA (September 2016)

World Congress of Brachytherapy, American Brachytherapy Society GEC ESTRO Joint Meeting. San Francisco, CA (June 2016)

American Radium Society Annual Meeting, Philadelphia, PA (April 2016)

Optimizing MRI-Guided Radiotherapy Symposium. Washington University, St-Louis, MI (May 2015)

American Society of Therapeutic Radiation Oncology (ASTRO) Leadership Workshop; Miami, FL (October, 2014)

American Radium Society Annual Meeting, St Thomas Island (April 2014)

American Association of Medical College Mid-Career Women Faculty Professional Development Seminar, Austin, TX (March, 2013)

American Society of Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Boston, MA (September 2013)

TheraSphere for Liver Cancer Treatment Training Session ; Chicago, IL (January, 2011)

American Society of Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Miami, FL (September 2011)

American Society of Therapeutic Radiation Oncology (ASTRO) Annual Meeting, San Diego, CA (September 2010)

Image Guided Brachytherapy for Gynecological Cancer Workshop. American Brachytherapy School. Chicago, IL (June 2009)

American Society of Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Chicago, IL (October 2009)

American Society of Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Boston MA (October 2008)

Leadership Program Symposium. Mc Gill University Health Center (MUHC) Montreal, QC, Canada Session #1 Managing conflict situations (November, 2006)3 Session #2 Leading in a change environment (February, 2007)

Image Guided Brachytherapy for Gynecological Cancer Workshop. European Society of Therapeutic Radiation Oncology (ESTRO). Vienna, Austria (August, 2006)

American Society of Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Denver, CO (October 2005)

Human Participants Protection Education for Research Teams, National Institute of Health (NIH) Online Training (November, 2001)

American Society of Therapeutic Radiation Oncology (ASTRO) Annual Meeting, San Antonio, TX (October 2000)

American Society of Therapeutic Radiation Oncology (ASTRO) Media Training Seminar ;  
Orlando, FL (October, 1997)

### Personnal Professional Development in Education

Project Management and Planning; Education Development Office (EDO) University of Miami  
(May 17, 2017)

Building an Educator portfolio; Rose Maria van Zuilen, PhD. Education Development Office  
(EDO) University of Miami (March 28, 2017)

| McGill University Faculty Medicine Development Workshops            |         |
|---|---------|
| The Use of Answers Device for Interactive Teaching                  | 04/2009 |
| Can MEds ROles and other Competencies                               | 11/2004 |
| Evaluating Residents Overcoming Obstacles                           | 04/2004 |
| Making the Implicit Explicit ; Advanced Clinical Teaching Skills    | 12/2003 |
| Actions Speak Louder than Words : Promoting Interaction in Teaching | 10/2003 |
| The Problem Student and Residents. Who's problem is it ?            | 05/2003 |
| Effective Lecturing and Audiovisual Aids                            | 05/1998 |

## VI. Teaching

### 28. Teaching Awards Received

Inducted Fellow of the Academy for Medical Educators. University of Miami (04/2017)

Teacher of the year McGill University Radiation Oncology Residency Program (06/2006)

Each year the trainees from the residency program elected a faculty (from a pool of 15 physicians) as the teacher of the year

### 29. Teaching Specialization:

#### Personal Professional Development as a Medical Educator

Participant, McGill University Faculty Development Workshop

|  |         |
|--|---------|
| The use of answers device for interactive teaching                 | 04/2009 |
| Evaluating residents overcoming obstacles                          | 04/2004 |
| Can Meds Roles and other Competencies                              | 11/2004 |
| Making the Implicit Explicit; Advanced Clinical Teaching Skills    | 12/2003 |
| Actions Speak Louder than Words: Promoting Interaction in Teaching | 10/2003 |
| The Problem Student and Residents. Who's Problem is it?            | 05/2003 |

Effective Lecturing and Audiovisual Aids

05/1998

Graduate, McGill University Teaching Scholar Program; McGill University, Montreal, QC, Canada (2003-2004)

### **Teaching Service**

Member, Radiation Oncology Residency Program Committee, University of Miami.  
(2010-present)

My role on the committee include to participate to meetings to review files of residents in difficulties, elaborate teaching initiative, participate to residents interview, participate to annual MOCK exams for the senior radiation oncology residents

Residency Program Director, Radiation Oncology Residency Program McGill University (2003-2006). The McGill University Radiation Oncology Residency Program was a five years training program accredited by the Royal College of Canada. The program had an average of 12 residents. It was one of the largest radiation oncology residency program in Canada

Chair, McGill Oncology Interdisciplinary Committee (2003-2010)

Examiner Oral Board Royal College of Physicians and Surgeons Canada, December 2004 to June 2009

Examiner Oral Examination, License Medical Council Canada, October 2003 to May 2010

### **Graduate Medical Education**

#### **Formal Lectures**

Radiation Oncology Residency Program

University of Miami Radiation Oncology Residency Program:

Radiobiology Applied to Brachytherapy (2 hours / year) (2014-present)

Gynecological Cancer Planning Sessions (2 hours / year) (2010-present)

Gastro Intestinal Cancer Planning Sessions (2 hours / year) (2010-present)

McGill University Radiation Oncology Residents, similar topics (6 hrs. / year) (2002-2010)

Other Oncology Graduate Program

University of Miami Medical Oncology Fellows

The role of radiation therapy in the management of rectal cancer (1 hour lecture) (January 2017)

The role of radiation therapy in the management of esophageal cancer (1 hour lecture) (May 2015)

The role of radiation therapy in the management of rectal cancer (1 hour lecture) (May 2015)

The role of radiation therapy in the management of pancreas cancer (1 hour lecture) (May 2014)

University of Miami Gynecology Oncology Fellows

Essentials of Brachytherapy for Gynecological Cancer Oral Board Preparation (1 hour lecture) (March 2017)

McGill University Interdisciplinary Oncology Program (2 hours /Month, September to June)

(2003-2010)

Other lectures to post graduate students:

Oncology PhD Program McGill University

Experimental and Clinical Oncology Course, Aerodigestive Cancer and Genetics Defects section (3 hrs. lecture) (November 2004 and December 2007)

### **Informal teaching activities**

Sylvester Comprehensive Cancer Center 2010-present

Faculty discussant, Gastrointestinal Tumor Board 1.5 hour/week x 40 weeks/year

Faculty discussant, Gynecology Oncology Tumor Board 1.5 hour/week x 40 weeks/year

Faculty discussant, Radiation Oncology Charts Rounds 1.5 hour/week x 40 weeks/year

Teaching attending, Radiation Oncology Clinic Resident supervision 16 hours/week x 40 weeks/year

Examiner, Mock Oral Board Exam Radiation Oncology Residents 10 hours per year

### **Undergraduate**

#### **Formal lectures**

4<sup>th</sup> year Medical Students; McGill University

Back to Basics Seminar on Gynecological Cancer (3 hours-seminar annually 2003-2007)

Multidisciplinary teaching sessions designed by a pathologist, a gyneco oncologist and myself; case based interactive education

3<sup>rd</sup> year Medical Students, McGill University

Introduction to Radiation Therapy (3 hours-seminar annually 2002-2004)

Teaching session for 3<sup>rd</sup> year medical students during their oncology introduction to clinical medicine (ICM) rotation

#### **Informal Teaching**

University of Miami

Radiation oncology Clinic 8 hours per student 09/2010-present

Every academic year about ten medical students from University of Miami and other institutions come to our department as observers. During these rotations, they have a one-two day rotation on my service.

McGill University

Multidisciplinary Gynecology Oncology Clinic 3 hours/week 40 weeks /year 09/2002-09/2010

Every Friday morning in the multidisciplinary Gynecology-Oncology clinic, 3<sup>rd</sup> year medical students joined our group during their gynecology rotation. During these clinic I was teaching medical students skills to conduct a medical interview, physical examination and basics on

management of gynecological cancer

### **Teaching to Other Health Professionals**

Portelance L. Radiation Safety Training

Jackson Memorial Hospital, Miami FL. Gynecology Ward Nurses (1 hour teaching session) (November 2011)

In service training for nurses working on a ward where patients were admitted for low dose rate brachytherapy for gynecological cancer. Teaching delivered in two separate sessions to accommodate nurses working on different teams.

Portelance, L. Research in Collaborative Groups in USA

Sylvester Comprehensive Cancer Center, Miami FL. Clinical Research Services Monitors University of Miami (1 hr. teaching session) (November, 2011)

Portelance L, The role of Radiation Therapy in the Management of Gynecological Cancer.

Jackson Memorial Hospital, Miami FL. Gynecology Ward Nurses (1 hour teaching session) (October, 2010)

Portelance, L. Gynecological Cancer Staging Quebec Medical Registrars Training Program (2 hrs. teaching session) (2007 and 2008)

Portelance, L. Treatment of Vaginal Cancer, Vulvar Cancer, Endometrial Cancer, Cervix Cancer Dawson College Radiation Technology Program. Teaching to Radiation Oncology Technology students. (Four 2 hours teaching sessions) (May, 1998)

### **Grand Rounds**

\*Only grand rounds given since 2010 are listed here

The role of Yttrium-90 in the management of Hepatocellular Carcinoma  
Liver Research Group Grand Round, University of Miami (12/2016)

The University of Miami Yttrium 90 Program

Radiation Oncology Grand Round, University of Miami (06/2016)

Yttrium-90 for Liver Metastasis and its Role in the Management of Breast Cancer Patients  
Breast Site Disease Group Meeting, University of Miami (09/2015)

Management of Pancreas Cancer;

Radiation Oncology Grand Round, University of Miami (06/2015)

Management of Rectal Cancer

Radiation Oncology Grand Round, University of Miami (06/2013)

Management of Hepatocellular Carcinoma

Radiation Oncology Grand Round, University of Miami (06/2012)

### **Mentoring**

**Undergraduate, Postgraduate, Residents, Fellows**

| Dates     | Name                 | Program or School                        | Project   |
|-----------|----------------------|--|---|
| 2017-pres | Steven Ramey, MD     | Resident                                 | NCDB analysis of waiting to initiate treatment for patients with cervical and anal canal cancer<br>Both projects have been accepted for poster presentation in a national meeting.<br>Manuscript for the cervical cancer cohort is finalized and submitted for publication.   |
| 2016-pres | David Asher, MD      | Resident                                 | Pattern of care study on the use of eye plaque for the treatment of retinal melanoma in USA and Canada. Analysis ongoing.   |
| 2016-pres | Loruanma Lam         | Undergrad. student<br>FIU                | Analysis of waiting time between diagnosis and radiation treatment start for patients diagnosed with locally advanced cervical cancer and treated in the University of Miami Health care system. Results will be compared to NCDB data from Dr. Ramey's study   |
| 2016-pres | Ricardo Llorente, MD | Post doc                                 | 1) Dosimetric analysis of four radiation therapy modalities to deliver a boost for patients with rectal cancer. Manuscript submitted in a peer reviewed journal 03/2017<br>2) Daily on board MRI to assess target motion in the management of cervical cancer; analysis is ongoing.<br>3) The role of radiation therapy in the management of patients diagnosed with stage IV anal canal cancer. Post doc learned all steps from protocol writing, to IRB submission, to data capture in a databank and will perform analysis once data capture is completed. |
| 2016-pres | Shefali Gajjar, MD   | Resident                                 | The use of radiation therapy and nanoknife in the management of locally advanced pancreas cancer<br>Project accepted for poster presentation in a national meeting; manuscript being written  |
| 2015      | Sofia Palacio, MD    | Med Onc Fellow                           | Prevalence of radiologic evidence of metastatic pancreatic cancer at first post operative restaging study in patient undergoing pancreas cancer surgery with intent to cure. Project accepted for poster presentation in a national gastrointestinal cancer meeting.<br>Project is now being expanded to add radiogenomics data.  |
| Dates     | Name                 | Program or School                        | Project   |
| 2013-2014 | Anabel Miguelez      | Howard Hugues Medical Institute Research | Databank project Y-90 radio embolization registry<br>Conducted a retrospective analysis of Yttrium-90 radio embolization for liver metastasis from neuroendocrine cancer; a single institution retrospective review. Project accepted for a poster  |

|                 |                       |   |   |
|-----------------|-----------------------|---|---|
|                 |                       | Program   | presentation in a national meeting.   |
| 2012            | Dan Cohen             | Med. Student                                      | Comparison of two planning strategy for vaginal vault brachytherapy. Project accepted for an oral presentation in a national meeting.   |
| 2010            | Servan Rajakesari, MD | Resident  | Dosimetric comparison of brachytherapy versus tomotherapy versus stereotactic body radiotherapy (SBRT) for the delivery of a rectal boost. Project accepted for poster presentation In two national meetings.   |
| 2010            | Fleure Gallant, MD    | Resident  | Needs assessment and development of an e-learning module on head and neck anatomy for residents in radiation oncology. Project accepted for an oral poster presentation, in a national meeting; learning module now on University of Miami Radiation Oncology Department website  |
| 2009-2010       | Joanne Alfieri, MD    | Resident  | Randomized control study on the efficacy of web based learning versus traditional learning for radiation oncology residents. Project accepted for poster presentation in a national meeting/<br>Won award for best residents research project in Canadian annual meeting and Quebec annual meeting of radiation oncology<br>Project also published in a peer reviewed journal |
| 2009            | Rania Ashem, MD       | Resident  | The impact of oral contrast on radiation therapy planning; an RTOG 0418 sub analysis<br>Project accepted for an oral presentation in a national meeting; manuscript in revision   |
| 2008            | Hasisen Patone, MD    | Resident  | Dosimetric comparison of two high dose rate brachytherapy planning system in cervix cancer: Project accepted for poster presentation in two national and one international brachytherapy meetings and published in a peer reviewed journal  |
| 08/2007-03/2008 | Monique Bloemers, MD  | International Fellow from Amsterdam<br>UICC grant | 1) Intensity modulated radiation therapy for vulvar cancer. Project accepted for poster presentation in two national meetings and published in a peer reviewed journal<br>2) Literature review ovarian function after a course of pelvic radiation. Project published in a medical journal  |
| 2004            | Joanne Alfieri        | Medical Student                                   | Development of a Gynecology oncology web based learning module<br>Project accepted for poster presentation in many national meetings  |

### Faculty Mentoring

| Date  | Name    | Position while mentored | Mentoring Role                                     |
|-------|---------|-------------------------|--|
| 2014- | Raphael | Assistant               | Junior faculty mentored in establishing a clinical |

|           |                  |  |  |
|-----------|------------------|--|--|
|           | Yechieli, MD     | professor  | practice in an academic cancer. This physician demonstrated from the beginning an interest in assuming a leadership role in the department. In June 2016, he was invited to take over my role as a medical co-director in Jackson Memorial Hospital and I am mentoring in during the transition.                           |
| 2010-2012 | Omar Mahmoud, MD | Clinical instructor; Dr Mahmoud is now an Assistant professor in an academic center. | I have mentored this physician in clinical research, guided him through protocol writing while he was writing a multidisciplinary databank protocol for patients diagnosed with anal canal cancer at University of Miami. I have also mentored doctor Mahmoud in preparing abstracts for submission for national meetings. |

## VII. SERVICE

### 31. University Committees and Administrative Responsibilities:

Member, Medical Care Review Committee. Sylvester Comprehensive Cancer Center; Miami, FL (01/2016-present)

Vice Chair, Department of Radiation Oncology. Miller School of Medicine; University of Miami, Miami, FL (2012-present)

Director, Clinical Research Program, Department of Radiation Oncology. Miller School of Medicine; University of Miami, Miami, FL (2010-present)

Member, Radiation Oncology Residency Program Committee. Miller School of Medicine, University of Miami (01/2011-present)

Member, American Cancer Society Grant Review. Sylvester Comprehensive Cancer Center; Miami, FL (04/2015-present)

Member, Clinic Advisory Committee. Sylvester Comprehensive Cancer Center; Miami, FL (01/2015 present)

Member, Research Advisory Committee. Sylvester Comprehensive Cancer Center; Miami, FL (01/2015-present)

Member, UMMG Leadership Council At-large Representatives. University of Miami Health System; Miami, FL 05/2013-12/2016

Member, Search Committee Gastro Intestinal Medical Oncologist. University of Miami, Miami, FL (2015)

Member, Search Committee Surgical Oncology Chair. University of Miami, Miami, FL (2014)

Member, Sylvester Poster Competition Review Committee Zubrod Day. University of Miami; Miami, FL (05/15/2015)

Member, Award program Review Panel, Miami CTSI-K12. University of Miami; Miami, FL (03/06/2013)

Member, Executive Council of Physicians, Dentists and Pharmacists. McGill University Health Centre (MUHC); Montreal, QC, Canada (05/2009-08/2010)

Member, Annual Research Retreat Organization Committee. McGill University Oncology Department (09/2006-09/2010)

Principal Investigator, McGill Gynecology Oncology Group (GOG) Affiliation (06/2006-04/2010)

Member, Lung Cancer Research Committee. Clinical Trials Unit, McGill University (2002-2010)

Member, Women's Cancer Research Committee. Clinical Trials Unit, McGill University (2004-2010)

Internal Reviewer, Gastroenterology and Anesthesiology Residency Program. Internal Review, McGill University, Montreal, QC, Canada (04/2010)

Member, Gynecology-Oncology Residency Program Committee. McGill University, Montreal, QC, Canada (2009-2010)

Member, Medical Physics Residency Program Committee. McGill University, Montreal, QC, Canada (2005-2010)

Member, Surgical Oncology Fellowship Program Committee. McGill University, Montreal, QC, Canada. (09/2002-2010)

Member, Medical Oncology Residency Program Committee. McGill University, Montreal, QC, Canada (09/2002-2010)

Member, Radiation Oncology Residency Program Committee. McGill University, Montreal, QC, Canada (09/2000-2008)

Member, Planning Committee for the Future University Hospital Center. McGill University Health Center (MUHC); Montreal, QC, Canada (01/2008-10/2009)

Member, Organization Committee. International Union Against Cancer (IUCC) meeting Montreal 2012. Montreal, QC, Canada (06/2007-09/2010)

Member, Implementation Committee ARIA Electronic File. Radiation Oncology Department McGill University Health Center (MUHC); Montreal QC, Canada (01/2008-2010)

Member, Implementation Committee for the Electronic Medical Record. McGill University Health Center (MUHC); Montreal QC, Canada (09/2007-2010)

Radiation Oncology Residency Program Director. McGill University, Montreal QC, Canada (01/2003-07/2006)

Internal Reviewer, Anesthesiology Residency Program Internal Review. McGill University, Montreal, QC, Canada (03/2006)

Developer of an electronic dictation system linked to a database for automatic data collection. Radiation Oncology Department. McGill University Health Center (MUHC); Montreal, QC, Canada (01/2004-01/2005)

Physician Examiner, Part II Oral examination Canadian Medical Licensing Board. Jewish General Hospital, Montreal, QC, Canada. (2003-2010)

Physician Examiner, Radiation Oncology specialty Canadian Royal College of Physicians and Surgeons (12/2004-06/2009)

Member, Selection Committee for the Miriam and Saul Goldberg Innovative Research Award, McGill University Cancer Centre (09/2004 and 05/2005)

Participant, Faculty of Medicine Retreat M.D.C.M. Curriculum Renewal, McGill University, Montreal, QC, Canada (09. 2004)

Member, Oncology Hospital Committee. Centre Hospitalier des Vallées de l'Outaouais (CHVO), Gatineau, QC, Canada (2000-2002)

Member, Regional Comité de lutte contre le cancer Outaouais division; Gatineau, QC, Canada (1999-2000)

### **Industry Committees**

Sirtex Advisory Board Meeting; Miami, FL (January 2013)

Astra-Zeneca Advisory Board Committee Iressa Clinical Experience Meeting, Sacacomie, QC, Canada (September 2004)

Lilly Oncology Advisory Board Meeting Management of NSCLC, Toronto, ON, Canada (May 2004)

Astra-Zeneca Advisory Board Committee on the Use of EGFR Inhibitor in the Treatment of Lung Cancer, Montreal, QC, Canada (August 2003)

Participant and presenter Quebec Targeted Therapy Committee Meeting, Orford, QC, Canada (March 2003)

### **32. Community Activities:**

#### **Dolphin Cycling Challenge**

For the third time this year I participated in this Sylvester Comprehensive Cancer Center fundraising event and went for a 35 miles bike ride to raise money for cancer research  
2010, 2016 and 2017 Editions

**Quebec Cancer Foundation**

Vice-President 2002-2010

Member, Board of Director 2000-2002

The Quebec Cancer Foundation is a non for profit organization offering services to patients diagnosed with cancer. Services offered include: hotels, art therapy, massage therapy, support groups...

One of my functions as the vice president of the Quebec Cancer Foundation was to address journalist's needs to disseminate cancer information to the general public. This is how I provided a medical expert opinion for many articles published in Quebec magazines or for radio/television broadcasts.

Examples of Work as a Medical Expert Quebec Cancer Foundation

Chatelaine Magazine, Article on ovarian cancer, diagnosis and treatment (03/2010)

Madame Magazine, Article on the prevention/ early diagnosis of breast cancer (07/2006)

Quebec Science magazine, risk of breast cancer induced by the use of antiperspirant (06/2006)

Radio-Canada RDI Interview on the Role of Radiation Oncology in Cancer Treatment (04/2006)

Editor

Patients and family information booklet «La radiothérapie et vous », Quebec Cancer Foundation (06/2009)